2024-04-05 02:25:18,558 - INFO - root - Logger initialized
2024-04-05 02:25:18,576 - INFO - root - Logger initialized
2024-04-05 02:25:18,577 - INFO - root - Processing File: 1
2024-04-05 02:25:18,577 - INFO - root - Successfully chunked the document!
2024-04-05 02:25:18,579 - INFO - root - Processing chunks 1/7
2024-04-05 02:25:47,986 - INFO - httpx - HTTP Request: POST https://api.anthropic.com/v1/complete "HTTP/1.1 200 OK"
2024-04-05 02:25:47,991 - INFO - root - Prediction:  Here are the samples extracted from the given article:

<sample>
{'input': 'Currently, Cholecystitis cannot be definitively diagnosed through a single examination. Diagnosis relies primarily on 
a thorough medical history, symptoms, physical examination, and imaging findings.',
'output': [{'entity1': 'Cholecystitis', 'relationship': 'diagnosed', 'entity2': 'medical history, symptoms, physical examination and imaging findings'}]}
</sample>

<sample>
{'input': 'The gold standard for differentiating 
between acute and chronic cholecystitis is the use of pathologic findings from cholecystectomy.',  
'output': [{'entity1': 'pathologic findings from cholecystectomy', 'relationship': 'differentiating', 'entity2': 'acute and chronic cholecystitis'}]}
</sample>

<sample>
{'input': 'While 
ultrasonography  is  commonly  used,  it  may  not  provide  conclusive  results  in  some  patients.',
'output': [{'entity1': 'ultrasonography', 'relationship': 'not provide conclusive results', 'entity2': 'some patients'}]}  
</sample>

<sample>
{'input': 'Computed 
tomography 
(CT)  has  its  limitations,  including  the  risk  of  false-positive  and  false-negative  diagnoses,  radiation 
exposure, and 
potential  nephrotoxic  effects  from  contrast  media.',
'output': [{'entity1': 'Computed tomography', 'relationship': 'limitations', 'entity2': 'false-positive diagnoses'}, {'entity1': 'Computed tomography', 'relationship': 'limitations', 'entity2': 'false-negative diagnoses'}, {'entity1': 'Computed tomography', 'relationship': 'risk', 'entity2': 'radiation exposure'}, {'entity1': 'contrast media', 'relationship': 'effects', 'entity2': 'potential nephrotoxic effects'}]}
</sample>

<sample>
{'input': 'Magnetic resonance imaging 
(MRI)  is  accurate  in  differentiating 
ACC from CCC due to its superior soft-tissue contrast resolution,', 
'output': [{'entity1': 'Magnetic resonance imaging', 'relationship': 'differentiating', 'entity2': 'acute calculus cholecystitis and chronic calculus cholecystitis'}]}
</sample>  

<sample>  
{'input': 'Tokyo Guidelines 2018 (TG18) is 
a  widely  accepted  standard  for  assessing  the  severity  of  ACC  using  scoring  systems.',
'output': [{'entity1': 'Tokyo Guidelines 2018', 'relationship': 'assessing severity', 'entity2': 'acute calculus cholecystitis'}]}
</sample>

<sample>  
{'input': 'white  blood  cell  (WBC)  count  and  leukocyte  subtype  cells  are  valuable 
indicators  for  predicting  the  inflammatory  process  in  acute  cholecystitis.',
'output': [{'entity1': 'white blood cell count', 'relationship': 'indicators', 'entity2': 'predicting inflammatory process in acute cholecystitis'}, {'entity1': 'leukocyte subtype cells', 'relationship': 'indicators', 'entity2': 'predicting inflammatory process in acute cholecystitis'}]}  
</sample>

<sample>
{'input': 'WBC  count  has  been  established  as  the 
primary biomarker for assessing the severity of cholecystitis.',  
'output': [{'entity1': 'WBC count', 'relationship': 'biomarker', 'entity2': 'assessing severity of cholecystitis'}]}
</sample>

<sample>
{'input': 'Several  inflammatory  parameters  based  on  WBC  and  platelet  counts,  such  as  the  neutrophil-to-lymphocyte 
ratio  (NLR),  platelet-to-lymphocyte  ratio  (PLR),  systemic  immune-inflammation  index  (SII),  and  neutrophil-to- 
lymphocyte  platelet  ratio  (NLPR),  as  potential  valuable  indicators  in  assessing  the  inflammatory  process.',
'output': [{'entity1': 'neutrophil-to-lymphocyte ratio', 'relationship': 'indicators', 'entity2': 'assessing inflammatory process'}, 
           {'entity1': 'platelet-to-lymphocyte ratio', 'relationship': 'indicators', 'entity2': 'assessing inflammatory process'},
           {'entity1': 'systemic immune-inflammation index', 'relationship': 'indicators', 'entity2': 'assessing inflammatory process'}, 
           {'entity1': 'neutrophil-to-lymphocyte platelet ratio', 'relationship': 'indicators', 'entity2': 'assessing inflammatory process'}]}
</sample>
2024-04-05 02:25:47,993 - INFO - root - Processed Output: [{'input': 'Currently, Cholecystitis cannot be definitively diagnosed through a single examination. Diagnosis relies primarily on a thorough medical history, symptoms, physical examination, and imaging findings.', 'output': [{'entity1': 'Cholecystitis', 'relationship': 'diagnosed', 'entity2': 'medical history, symptoms, physical examination and imaging findings'}]}, {'input': 'The gold standard for differentiating between acute and chronic cholecystitis is the use of pathologic findings from cholecystectomy.', 'output': [{'entity1': 'pathologic findings from cholecystectomy', 'relationship': 'differentiating', 'entity2': 'acute and chronic cholecystitis'}]}, {'input': 'While ultrasonography  is  commonly  used,  it  may  not  provide  conclusive  results  in  some  patients.', 'output': [{'entity1': 'ultrasonography', 'relationship': 'not provide conclusive results', 'entity2': 'some patients'}]}, {'input': 'Computed tomography (CT)  has  its  limitations,  including  the  risk  of  false-positive  and  false-negative  diagnoses,  radiation exposure, and potential  nephrotoxic  effects  from  contrast  media.', 'output': [{'entity1': 'Computed tomography', 'relationship': 'limitations', 'entity2': 'false-positive diagnoses'}, {'entity1': 'Computed tomography', 'relationship': 'limitations', 'entity2': 'false-negative diagnoses'}, {'entity1': 'Computed tomography', 'relationship': 'risk', 'entity2': 'radiation exposure'}, {'entity1': 'contrast media', 'relationship': 'effects', 'entity2': 'potential nephrotoxic effects'}]}, {'input': 'Magnetic resonance imaging (MRI)  is  accurate  in  differentiating ACC from CCC due to its superior soft-tissue contrast resolution,', 'output': [{'entity1': 'Magnetic resonance imaging', 'relationship': 'differentiating', 'entity2': 'acute calculus cholecystitis and chronic calculus cholecystitis'}]}, {'input': 'Tokyo Guidelines 2018 (TG18) is a  widely  accepted  standard  for  assessing  the  severity  of  ACC  using  scoring  systems.', 'output': [{'entity1': 'Tokyo Guidelines 2018', 'relationship': 'assessing severity', 'entity2': 'acute calculus cholecystitis'}]}, {'input': 'white  blood  cell  (WBC)  count  and  leukocyte  subtype  cells  are  valuable indicators  for  predicting  the  inflammatory  process  in  acute  cholecystitis.', 'output': [{'entity1': 'white blood cell count', 'relationship': 'indicators', 'entity2': 'predicting inflammatory process in acute cholecystitis'}, {'entity1': 'leukocyte subtype cells', 'relationship': 'indicators', 'entity2': 'predicting inflammatory process in acute cholecystitis'}]}, {'input': 'WBC  count  has  been  established  as  the primary biomarker for assessing the severity of cholecystitis.', 'output': [{'entity1': 'WBC count', 'relationship': 'biomarker', 'entity2': 'assessing severity of cholecystitis'}]}, {'input': 'Several  inflammatory  parameters  based  on  WBC  and  platelet  counts,  such  as  the  neutrophil-to-lymphocyte ratio  (NLR),  platelet-to-lymphocyte  ratio  (PLR),  systemic  immune-inflammation  index  (SII),  and  neutrophil-to- lymphocyte  platelet  ratio  (NLPR),  as  potential  valuable  indicators  in  assessing  the  inflammatory  process.', 'output': [{'entity1': 'neutrophil-to-lymphocyte ratio', 'relationship': 'indicators', 'entity2': 'assessing inflammatory process'}, {'entity1': 'platelet-to-lymphocyte ratio', 'relationship': 'indicators', 'entity2': 'assessing inflammatory process'}, {'entity1': 'systemic immune-inflammation index', 'relationship': 'indicators', 'entity2': 'assessing inflammatory process'}, {'entity1': 'neutrophil-to-lymphocyte platelet ratio', 'relationship': 'indicators', 'entity2': 'assessing inflammatory process'}]}]
2024-04-05 02:25:48,012 - INFO - root - New Rows:     id                                              input                                             output
0  460  Currently, Cholecystitis cannot be definitivel...  [{'entity1': 'Cholecystitis', 'relationship': ...
1  461  The gold standard for differentiating between ...  [{'entity1': 'pathologic findings from cholecy...
2  462  While ultrasonography  is  commonly  used,  it...  [{'entity1': 'ultrasonography', 'relationship'...
3  463  Computed tomography (CT)  has  its  limitation...  [{'entity1': 'Computed tomography', 'relations...
4  464  Magnetic resonance imaging (MRI)  is  accurate...  [{'entity1': 'Magnetic resonance imaging', 're...
5  465  Tokyo Guidelines 2018 (TG18) is a  widely  acc...  [{'entity1': 'Tokyo Guidelines 2018', 'relatio...
6  466  white  blood  cell  (WBC)  count  and  leukocy...  [{'entity1': 'white blood cell count', 'relati...
7  467  WBC  count  has  been  established  as  the pr...  [{'entity1': 'WBC count', 'relationship': 'bio...
8  468  Several  inflammatory  parameters  based  on  ...  [{'entity1': 'neutrophil-to-lymphocyte ratio',...
2024-04-05 02:25:48,020 - INFO - root - Successfully saved to dataframe!
2024-04-05 02:25:48,025 - INFO - root - Processing chunks 2/7
2024-04-05 02:26:12,502 - INFO - httpx - HTTP Request: POST https://api.anthropic.com/v1/complete "HTTP/1.1 200 OK"
2024-04-05 02:26:12,502 - INFO - root - Prediction:  Here are the training samples extracted from the given article:

<sample>
{'input': 'This prospective, observational, and single-center study was conducted at the hepatobiliary surgery of Wenzhou Central 
Hospital. The research was carried out from June 2022 to September 2023, involving 250 patients who had undergone 
cholecystectomy  due  to  ACC  or  CCC.',
'output': [{'entity1': 'study', 'relationship': 'conducted at', 'entity2': 'hepatobiliary surgery of Wenzhou Central Hospital'}, 
           {'entity1': 'study', 'relationship': 'involving', 'entity2': '250 patients'},
           {'entity1': '250 patients', 'relationship': 'undergone', 'entity2': 'cholecystectomy'},
           {'entity1': 'cholecystectomy', 'relationship': 'due to', 'entity2': 'ACC or CCC'}]}
</sample>

<sample>
{'input': 'Histopathological  examination  was  performed  on  the  resected  gallbladders.',
'output': [{'entity1': 'Histopathological examination', 'relationship': 'performed on', 'entity2': 'resected gallbladders'}]}
</sample>

<sample>  
{'input': 'Diagnosis of CCC and ACC before surgery primarily relied on a combination of detailed medical history, comprehensive 
clinical examination, laboratory tests, and imaging investigations.',
'output': [{'entity1': 'Diagnosis', 'relationship': 'relied on', 'entity2': 'medical history'}, 
           {'entity1': 'Diagnosis', 'relationship': 'relied on', 'entity2': 'clinical examination'},
           {'entity1': 'Diagnosis', 'relationship': 'relied on', 'entity2': 'laboratory tests'}, 
           {'entity1': 'Diagnosis', 'relationship': 'relied on', 'entity2': 'imaging investigations'}]}
</sample>

<sample>
{'input': 'The final confirmation of the diagnosis of both ACC and CCC was based on the pathological examination of  postoperative gallbladder tissue specimens.',  
'output': [{'entity1': 'final confirmation', 'relationship': 'based on', 'entity2': 'pathological examination'},
           {'entity1': 'pathological examination', 'relationship': 'of', 'entity2': 'postoperative gallbladder tissue specimens'}]}
</sample>

<sample>
{'input': 'The ACC patients underwent  further  classification  by  the  TG18  into  three  severity  grades:4  Moderate  ACC  is  related  to  any  one  of 
the  following  conditions:',
'output': [{'entity1': 'ACC patients', 'relationship': 'underwent', 'entity2': 'classification'},
           {'entity1': 'classification', 'relationship': 'by', 'entity2': 'TG18'},
           {'entity1': 'classification', 'relationship': 'into', 'entity2': 'three severity grades'},
           {'entity1': 'Moderate ACC', 'relationship': 'related to', 'entity2': 'conditions'}]}  
</sample>

<sample>
{'input': 'Patients  with  Moderate-  and  severe-degree inflammations  were  grouped  as  the  high-degree  inflammation  group  and  compared  with  the  mild-degree  inflammation group.',
'output': [{'entity1': 'Patients', 'relationship': 'grouped as', 'entity2': 'high-degree inflammation group'}, 
           {'entity1': 'high-degree inflammation group', 'relationship': 'compared with', 'entity2': 'mild-degree inflammation group'}]}
</sample>
2024-04-05 02:26:12,502 - INFO - root - Processed Output: [{'input': 'This prospective, observational, and single-center study was conducted at the hepatobiliary surgery of Wenzhou Central Hospital. The research was carried out from June 2022 to September 2023, involving 250 patients who had undergone cholecystectomy  due  to  ACC  or  CCC.', 'output': [{'entity1': 'study', 'relationship': 'conducted at', 'entity2': 'hepatobiliary surgery of Wenzhou Central Hospital'}, {'entity1': 'study', 'relationship': 'involving', 'entity2': '250 patients'}, {'entity1': '250 patients', 'relationship': 'undergone', 'entity2': 'cholecystectomy'}, {'entity1': 'cholecystectomy', 'relationship': 'due to', 'entity2': 'ACC or CCC'}]}, {'input': 'Histopathological  examination  was  performed  on  the  resected  gallbladders.', 'output': [{'entity1': 'Histopathological examination', 'relationship': 'performed on', 'entity2': 'resected gallbladders'}]}, {'input': 'Diagnosis of CCC and ACC before surgery primarily relied on a combination of detailed medical history, comprehensive clinical examination, laboratory tests, and imaging investigations.', 'output': [{'entity1': 'Diagnosis', 'relationship': 'relied on', 'entity2': 'medical history'}, {'entity1': 'Diagnosis', 'relationship': 'relied on', 'entity2': 'clinical examination'}, {'entity1': 'Diagnosis', 'relationship': 'relied on', 'entity2': 'laboratory tests'}, {'entity1': 'Diagnosis', 'relationship': 'relied on', 'entity2': 'imaging investigations'}]}, {'input': 'The final confirmation of the diagnosis of both ACC and CCC was based on the pathological examination of  postoperative gallbladder tissue specimens.', 'output': [{'entity1': 'final confirmation', 'relationship': 'based on', 'entity2': 'pathological examination'}, {'entity1': 'pathological examination', 'relationship': 'of', 'entity2': 'postoperative gallbladder tissue specimens'}]}, {'input': 'The ACC patients underwent  further  classification  by  the  TG18  into  three  severity  grades:4  Moderate  ACC  is  related  to  any  one  of the  following  conditions:', 'output': [{'entity1': 'ACC patients', 'relationship': 'underwent', 'entity2': 'classification'}, {'entity1': 'classification', 'relationship': 'by', 'entity2': 'TG18'}, {'entity1': 'classification', 'relationship': 'into', 'entity2': 'three severity grades'}, {'entity1': 'Moderate ACC', 'relationship': 'related to', 'entity2': 'conditions'}]}, {'input': 'Patients  with  Moderate-  and  severe-degree inflammations  were  grouped  as  the  high-degree  inflammation  group  and  compared  with  the  mild-degree  inflammation group.', 'output': [{'entity1': 'Patients', 'relationship': 'grouped as', 'entity2': 'high-degree inflammation group'}, {'entity1': 'high-degree inflammation group', 'relationship': 'compared with', 'entity2': 'mild-degree inflammation group'}]}]
2024-04-05 02:26:12,506 - INFO - root - New Rows:     id                                              input                                             output
0  469  This prospective, observational, and single-ce...  [{'entity1': 'study', 'relationship': 'conduct...
1  470  Histopathological  examination  was  performed...  [{'entity1': 'Histopathological examination', ...
2  471  Diagnosis of CCC and ACC before surgery primar...  [{'entity1': 'Diagnosis', 'relationship': 'rel...
3  472  The final confirmation of the diagnosis of bot...  [{'entity1': 'final confirmation', 'relationsh...
4  473  The ACC patients underwent  further  classific...  [{'entity1': 'ACC patients', 'relationship': '...
5  474  Patients  with  Moderate-  and  severe-degree ...  [{'entity1': 'Patients', 'relationship': 'grou...
2024-04-05 02:26:12,510 - INFO - root - Successfully saved to dataframe!
2024-04-05 02:26:12,514 - INFO - root - Processing chunks 3/7
2024-04-05 02:26:39,367 - INFO - httpx - HTTP Request: POST https://api.anthropic.com/v1/complete "HTTP/1.1 200 OK"
2024-04-05 02:26:39,369 - INFO - root - Prediction:  Here are the training samples extracted from the given article:

<sample>
{'input': 'Among the patients with ACC, there were 36 cases of mild-degree inflammation (M-ACC) and 52 cases of moderate- 
and  severe-degree  inflammation  (MS-ACC).', 
'output': [{'entity1': 'patients', 'relationship': 'have', 'entity2': 'mild-degree inflammation'}, 
           {'entity1': 'patients', 'relationship': 'have', 'entity2': 'moderate and severe degree inflammation'}]}
</sample>

<sample>
{'input': 'Severe ACC was present in only three patients, with one case involving hepatic dysfunction, another with respiratory complications, and the third demonstrating cardiological dysfunction.',
'output': [{'entity1': 'Severe ACC', 'relationship': 'present', 'entity2': 'patients'}, 
           {'entity1': 'case', 'relationship': 'involving', 'entity2': 'hepatic dysfunction'},
           {'entity1': 'case', 'relationship': 'involving', 'entity2': 'respiratory complications'}, 
           {'entity1': 'case', 'relationship': 'demonstrating', 'entity2': 'cardiological dysfunction'}]}
</sample>

<sample>
{'input': 'The average age of patients with M-ACC was 50.4 years, while for the MS-ACC group, it was 59.5 years.', 
'output': [{'entity1': 'average age', 'relationship': 'was', 'entity2': '50.4 years'}, 
           {'entity1': 'patients', 'relationship': 'have', 'entity2': 'M-ACC'},
           {'entity1': 'average age', 'relationship': 'was', 'entity2': '59.5 years'},  
           {'entity1': 'patients', 'relationship': 'have', 'entity2': 'MS-ACC'}]}
</sample>

<sample>  
{'input': 'Apo AI levels were notably lower in MS-ACC patients compared to those with M-ACC.',
'output': [{'entity1': 'Apo AI levels', 'relationship': 'lower', 'entity2': 'MS-ACC patients'}, 
           {'entity1': 'Apo AI levels', 'relationship': 'compared', 'entity2': 'M-ACC patients'}]}
</sample>

<sample>
{'input': 'Analysis of blood parameters revealed a significant increase in WBC and neutrophil counts in MS-ACC patients compared to M-ACC patients, whereas the lymphocyte count was significantly lower in the MS-ACC group than in the M-ACC group.', 
'output': [{'entity1': 'WBC count', 'relationship': 'increase', 'entity2': 'MS-ACC patients'},
           {'entity1': 'neutrophil count', 'relationship': 'increase', 'entity2': 'MS-ACC patients'},
           {'entity1': 'WBC count', 'relationship': 'compared', 'entity2': 'M-ACC patients'},
           {'entity1': 'neutrophil count', 'relationship': 'compared', 'entity2': 'M-ACC patients'},
           {'entity1': 'lymphocyte count', 'relationship': 'lower', 'entity2': 'MS-ACC group'},
           {'entity1': 'lymphocyte count', 'relationship': 'compared', 'entity2': 'M-ACC group'}]}
</sample>

<sample>
{'input': 'Furthermore, in MS-ACC patients, the NLR, SII, and NPLR values were significantly higher compared to M-ACC patients',   
'output': [{'entity1': 'NLR values', 'relationship': 'higher', 'entity2': 'MS-ACC patients'}, 
           {'entity1': 'SII values', 'relationship': 'higher', 'entity2': 'MS-ACC patients'},  
           {'entity1': 'NPLR values', 'relationship': 'higher', 'entity2': 'MS-ACC patients'},
           {'entity1': 'NLR values', 'relationship': 'compared', 'entity2': 'M-ACC patients'},
           {'entity1': 'SII values', 'relationship': 'compared', 'entity2': 'M-ACC patients'}, 
           {'entity1': 'NPLR values', 'relationship': 'compared', 'entity2': 'M-ACC patients'}]}
</sample>
2024-04-05 02:26:39,371 - INFO - root - Processed Output: [{'input': 'Among the patients with ACC, there were 36 cases of mild-degree inflammation (M-ACC) and 52 cases of moderate- and  severe-degree  inflammation  (MS-ACC).', 'output': [{'entity1': 'patients', 'relationship': 'have', 'entity2': 'mild-degree inflammation'}, {'entity1': 'patients', 'relationship': 'have', 'entity2': 'moderate and severe degree inflammation'}]}, {'input': 'Severe ACC was present in only three patients, with one case involving hepatic dysfunction, another with respiratory complications, and the third demonstrating cardiological dysfunction.', 'output': [{'entity1': 'Severe ACC', 'relationship': 'present', 'entity2': 'patients'}, {'entity1': 'case', 'relationship': 'involving', 'entity2': 'hepatic dysfunction'}, {'entity1': 'case', 'relationship': 'involving', 'entity2': 'respiratory complications'}, {'entity1': 'case', 'relationship': 'demonstrating', 'entity2': 'cardiological dysfunction'}]}, {'input': 'The average age of patients with M-ACC was 50.4 years, while for the MS-ACC group, it was 59.5 years.', 'output': [{'entity1': 'average age', 'relationship': 'was', 'entity2': '50.4 years'}, {'entity1': 'patients', 'relationship': 'have', 'entity2': 'M-ACC'}, {'entity1': 'average age', 'relationship': 'was', 'entity2': '59.5 years'}, {'entity1': 'patients', 'relationship': 'have', 'entity2': 'MS-ACC'}]}, {'input': 'Apo AI levels were notably lower in MS-ACC patients compared to those with M-ACC.', 'output': [{'entity1': 'Apo AI levels', 'relationship': 'lower', 'entity2': 'MS-ACC patients'}, {'entity1': 'Apo AI levels', 'relationship': 'compared', 'entity2': 'M-ACC patients'}]}, {'input': 'Analysis of blood parameters revealed a significant increase in WBC and neutrophil counts in MS-ACC patients compared to M-ACC patients, whereas the lymphocyte count was significantly lower in the MS-ACC group than in the M-ACC group.', 'output': [{'entity1': 'WBC count', 'relationship': 'increase', 'entity2': 'MS-ACC patients'}, {'entity1': 'neutrophil count', 'relationship': 'increase', 'entity2': 'MS-ACC patients'}, {'entity1': 'WBC count', 'relationship': 'compared', 'entity2': 'M-ACC patients'}, {'entity1': 'neutrophil count', 'relationship': 'compared', 'entity2': 'M-ACC patients'}, {'entity1': 'lymphocyte count', 'relationship': 'lower', 'entity2': 'MS-ACC group'}, {'entity1': 'lymphocyte count', 'relationship': 'compared', 'entity2': 'M-ACC group'}]}, {'input': 'Furthermore, in MS-ACC patients, the NLR, SII, and NPLR values were significantly higher compared to M-ACC patients', 'output': [{'entity1': 'NLR values', 'relationship': 'higher', 'entity2': 'MS-ACC patients'}, {'entity1': 'SII values', 'relationship': 'higher', 'entity2': 'MS-ACC patients'}, {'entity1': 'NPLR values', 'relationship': 'higher', 'entity2': 'MS-ACC patients'}, {'entity1': 'NLR values', 'relationship': 'compared', 'entity2': 'M-ACC patients'}, {'entity1': 'SII values', 'relationship': 'compared', 'entity2': 'M-ACC patients'}, {'entity1': 'NPLR values', 'relationship': 'compared', 'entity2': 'M-ACC patients'}]}]
2024-04-05 02:26:39,386 - INFO - root - New Rows:     id                                              input                                             output
0  475  Among the patients with ACC, there were 36 cas...  [{'entity1': 'patients', 'relationship': 'have...
1  476  Severe ACC was present in only three patients,...  [{'entity1': 'Severe ACC', 'relationship': 'pr...
2  477  The average age of patients with M-ACC was 50....  [{'entity1': 'average age', 'relationship': 'w...
3  478  Apo AI levels were notably lower in MS-ACC pat...  [{'entity1': 'Apo AI levels', 'relationship': ...
4  479  Analysis of blood parameters revealed a signif...  [{'entity1': 'WBC count', 'relationship': 'inc...
5  480  Furthermore, in MS-ACC patients, the NLR, SII,...  [{'entity1': 'NLR values', 'relationship': 'hi...
2024-04-05 02:26:39,393 - INFO - root - Successfully saved to dataframe!
2024-04-05 02:26:39,400 - INFO - root - Processing chunks 4/7
2024-04-05 02:27:00,493 - INFO - httpx - HTTP Request: POST https://api.anthropic.com/v1/complete "HTTP/1.1 200 OK"
2024-04-05 02:27:00,495 - INFO - root - Prediction:  Here are the samples extracted from the given article:

<sample>
{
    "input": "In addition, ROC Curve Analysis demonstrated that NLR, SII, and NLPR might be acceptable in the differentiation of 
M-ACC and MS-ACC patients. The areas under the curve (AUC) for NLR, SII, and NLPR were 0.760, 0.723, and 0.778, 
respectively.",
    "output": [
        {
            "entity1": "NLR",
            "relationship": "acceptable", 
            "entity2": "differentiation of M-ACC and MS-ACC patients"
        },
        {
            "entity1": "SII",
            "relationship": "acceptable",
            "entity2": "differentiation of M-ACC and MS-ACC patients"
        },
        {
            "entity1": "NLPR", 
            "relationship": "acceptable",
            "entity2": "differentiation of M-ACC and MS-ACC patients"
        }
    ]
}
</sample>

<sample>
{
    "input": "The optimal cut-off values were identified as 6.399, 1261, and 0.044 for NLR, SII, and NLPR. Sensitivities 

for NLR, SII, and NLPR were found to be 71.15%, 72.22%, and 61.54%, while specificities were 80.56%, 73.08%, and 
91.67%.",
    "output": [
        {
            "entity1": "NLR",
            "relationship": "cut-off value",
            "entity2": "6.399"  
        },
        {
            "entity1": "SII",
            "relationship": "cut-off value", 
            "entity2": "1261"
        },
        {
            "entity1": "NLPR",
            "relationship": "cut-off value",
            "entity2": "0.044"
        }
    ]
}
</sample>

<sample>
{
    "input": "Univariate  and  multivariable  binary  logistic  analyses  were  conducted  to  evaluate  the  clinical  significance  of 
Inflammation  Indices  as  biomarkers  in  distinguishing  between  ACC  and  CCC  patients.",
    "output": [
        {
            "entity1": "Inflammation Indices", 
            "relationship": "biomarkers", 
            "entity2": "distinguishing between ACC and CCC patients"
        }
    ]
} 
</sample>

<sample>
{
    "input": "It was shown that when the NLR was more than the cutoff value, there was an increased risk of (10.308 
times higher) moderate to severe degree inflammation compared to the lower NLR",
    "output": [
        {
            "entity1": "NLR",
            "relationship": "associated", 
            "entity2": "increased risk of moderate to severe degree inflammation"
        }
    ]
}
</sample>
2024-04-05 02:27:00,495 - INFO - root - Processed Output: [{'input': 'In addition, ROC Curve Analysis demonstrated that NLR, SII, and NLPR might be acceptable in the differentiation of M-ACC and MS-ACC patients. The areas under the curve (AUC) for NLR, SII, and NLPR were 0.760, 0.723, and 0.778, respectively.', 'output': [{'entity1': 'NLR', 'relationship': 'acceptable', 'entity2': 'differentiation of M-ACC and MS-ACC patients'}, {'entity1': 'SII', 'relationship': 'acceptable', 'entity2': 'differentiation of M-ACC and MS-ACC patients'}, {'entity1': 'NLPR', 'relationship': 'acceptable', 'entity2': 'differentiation of M-ACC and MS-ACC patients'}]}, {'input': 'The optimal cut-off values were identified as 6.399, 1261, and 0.044 for NLR, SII, and NLPR. Sensitivities for NLR, SII, and NLPR were found to be 71.15%, 72.22%, and 61.54%, while specificities were 80.56%, 73.08%, and 91.67%.', 'output': [{'entity1': 'NLR', 'relationship': 'cut-off value', 'entity2': '6.399'}, {'entity1': 'SII', 'relationship': 'cut-off value', 'entity2': '1261'}, {'entity1': 'NLPR', 'relationship': 'cut-off value', 'entity2': '0.044'}]}, {'input': 'Univariate  and  multivariable  binary  logistic  analyses  were  conducted  to  evaluate  the  clinical  significance  of Inflammation  Indices  as  biomarkers  in  distinguishing  between  ACC  and  CCC  patients.', 'output': [{'entity1': 'Inflammation Indices', 'relationship': 'biomarkers', 'entity2': 'distinguishing between ACC and CCC patients'}]}, {'input': 'It was shown that when the NLR was more than the cutoff value, there was an increased risk of (10.308 times higher) moderate to severe degree inflammation compared to the lower NLR', 'output': [{'entity1': 'NLR', 'relationship': 'associated', 'entity2': 'increased risk of moderate to severe degree inflammation'}]}]
2024-04-05 02:27:00,500 - INFO - root - New Rows:     id                                              input                                             output
0  481  In addition, ROC Curve Analysis demonstrated t...  [{'entity1': 'NLR', 'relationship': 'acceptabl...
1  482  The optimal cut-off values were identified as ...  [{'entity1': 'NLR', 'relationship': 'cut-off v...
2  483  Univariate  and  multivariable  binary  logist...  [{'entity1': 'Inflammation Indices', 'relation...
3  484  It was shown that when the NLR was more than t...  [{'entity1': 'NLR', 'relationship': 'associate...
2024-04-05 02:27:00,503 - INFO - root - Successfully saved to dataframe!
2024-04-05 02:27:00,509 - INFO - root - Processing chunks 5/7
2024-04-05 02:27:31,256 - INFO - httpx - HTTP Request: POST https://api.anthropic.com/v1/complete "HTTP/1.1 200 OK"
2024-04-05 02:27:31,258 - INFO - root - Prediction:  Here are the samples extracted from the given article:

<sample>
{'input': 'Considering the four inflammatory parameters associated with CC, NLR has been extensively studied and is considered 
a reliable marker for prognosticating diseases involving inflammatory and infective processes.20,21  Previous literature has 
shown that NLR is significantly higher in acute cholecystitis compared to healthy controls, ranging from 5.29–12.16 compared 
to 1.73–2.98.14,22–25',
'output': [{'entity1': 'NLR', 'relationship': 'marker', 'entity2': 'diseases involving inflammatory and infective processes'}, 
           {'entity1': 'NLR', 'relationship': 'higher', 'entity2': 'acute cholecystitis'}, 
           {'entity1': 'NLR in acute cholecystitis', 'relationship': 'compared to', 'entity2': 'NLR in healthy controls'}]}
</sample>

<sample>
{'input': 'Our study supports previous findings that NLR levels were significantly higher in acute cholecystitis 
compared to chronic cholecystitis.23 We found that an NLR value above 3.89 was significant in the ACC group compared to 
the CCC group, and above 6.399 was significant in the MS-ACC patients.', 
'output': [{'entity1': 'NLR levels', 'relationship': 'higher', 'entity2': 'acute cholecystitis'},
          {'entity1': 'NLR levels', 'relationship': 'compared to', 'entity2': 'chronic cholecystitis'},  
          {'entity1': 'NLR value above 3.89', 'relationship': 'significant', 'entity2': 'ACC group'},
          {'entity1': 'NLR value above 3.89', 'relationship': 'compared to', 'entity2': 'CCC group'},
          {'entity1': 'NLR value above 6.399', 'relationship': 'significant', 'entity2': 'MS-ACC patients'}]}
</sample>

<sample>
{'input': 'The binary logistic regression analysis revealed that 
an  NLR  exceeding  the  cutoff  value  independently  predicts  ACC  and  its  severity.',
'output': [{'entity1': 'NLR exceeding the cutoff value','relationship': 'predicts','entity2': 'ACC'},
           {'entity1': 'NLR exceeding the cutoff value','relationship': 'predicts','entity2': 'ACC severity'}]}
</sample>  

<sample>
{'input': 'Consistent with our findings, a study by Sang Kuon Lee et al observed a significant association between NLR and 
gangrenous cholecystitis (GC), where each standard deviation increase in NLR corresponded to a 48% heightened probability 
of GC.24',
'output': [{'entity1': 'NLR', 'relationship': 'association', 'entity2': 'gangrenous cholecystitis'},
          {'entity1': 'standard deviation increase in NLR', 'relationship': 'corresponded to', 'entity2': 'heightened probability of GC'}]}
</sample>

<sample>  
{'input': 'PLR, another inflammatory marker based on complete blood count values, has shown potential as a prognostic marker 
in inflammatory diseases and malignancies.',
'output': [{'entity1': 'PLR', 'relationship': 'marker', 'entity2': 'inflammatory diseases'}, 
          {'entity1': 'PLR', 'relationship': 'marker', 'entity2': 'malignancies'}]}
</sample>

<sample>
{'input': 'In our research, we observed that a PLR of 144.7 effectively distinguished 
between  ACC  and  CCC,  with  a  sensitivity  of  68.18%,  specificity  of  61.9%,  and  ROC  AUC  of  66.20%.',  
'output': [{'entity1': 'PLR of 144.7', 'relationship': 'distinguished','entity2': 'ACC'}, 
           {'entity1': 'PLR of 144.7', 'relationship': 'distinguished','entity2': 'CCC'}]}
</sample>

I have extracted all the meaningful samples I could find from the given article. Please let me know if you need any clarification or have additional requests.
2024-04-05 02:27:31,260 - INFO - root - Processed Output: [{'input': 'Considering the four inflammatory parameters associated with CC, NLR has been extensively studied and is considered a reliable marker for prognosticating diseases involving inflammatory and infective processes.20,21  Previous literature has shown that NLR is significantly higher in acute cholecystitis compared to healthy controls, ranging from 5.29–12.16 compared to 1.73–2.98.14,22–25', 'output': [{'entity1': 'NLR', 'relationship': 'marker', 'entity2': 'diseases involving inflammatory and infective processes'}, {'entity1': 'NLR', 'relationship': 'higher', 'entity2': 'acute cholecystitis'}, {'entity1': 'NLR in acute cholecystitis', 'relationship': 'compared to', 'entity2': 'NLR in healthy controls'}]}, {'input': 'Our study supports previous findings that NLR levels were significantly higher in acute cholecystitis compared to chronic cholecystitis.23 We found that an NLR value above 3.89 was significant in the ACC group compared to the CCC group, and above 6.399 was significant in the MS-ACC patients.', 'output': [{'entity1': 'NLR levels', 'relationship': 'higher', 'entity2': 'acute cholecystitis'}, {'entity1': 'NLR levels', 'relationship': 'compared to', 'entity2': 'chronic cholecystitis'}, {'entity1': 'NLR value above 3.89', 'relationship': 'significant', 'entity2': 'ACC group'}, {'entity1': 'NLR value above 3.89', 'relationship': 'compared to', 'entity2': 'CCC group'}, {'entity1': 'NLR value above 6.399', 'relationship': 'significant', 'entity2': 'MS-ACC patients'}]}, {'input': 'The binary logistic regression analysis revealed that an  NLR  exceeding  the  cutoff  value  independently  predicts  ACC  and  its  severity.', 'output': [{'entity1': 'NLR exceeding the cutoff value', 'relationship': 'predicts', 'entity2': 'ACC'}, {'entity1': 'NLR exceeding the cutoff value', 'relationship': 'predicts', 'entity2': 'ACC severity'}]}, {'input': 'Consistent with our findings, a study by Sang Kuon Lee et al observed a significant association between NLR and gangrenous cholecystitis (GC), where each standard deviation increase in NLR corresponded to a 48% heightened probability of GC.24', 'output': [{'entity1': 'NLR', 'relationship': 'association', 'entity2': 'gangrenous cholecystitis'}, {'entity1': 'standard deviation increase in NLR', 'relationship': 'corresponded to', 'entity2': 'heightened probability of GC'}]}, {'input': 'PLR, another inflammatory marker based on complete blood count values, has shown potential as a prognostic marker in inflammatory diseases and malignancies.', 'output': [{'entity1': 'PLR', 'relationship': 'marker', 'entity2': 'inflammatory diseases'}, {'entity1': 'PLR', 'relationship': 'marker', 'entity2': 'malignancies'}]}, {'input': 'In our research, we observed that a PLR of 144.7 effectively distinguished between  ACC  and  CCC,  with  a  sensitivity  of  68.18%,  specificity  of  61.9%,  and  ROC  AUC  of  66.20%.', 'output': [{'entity1': 'PLR of 144.7', 'relationship': 'distinguished', 'entity2': 'ACC'}, {'entity1': 'PLR of 144.7', 'relationship': 'distinguished', 'entity2': 'CCC'}]}]
2024-04-05 02:27:31,274 - INFO - root - New Rows:     id                                              input                                             output
0  485  Considering the four inflammatory parameters a...  [{'entity1': 'NLR', 'relationship': 'marker', ...
1  486  Our study supports previous findings that NLR ...  [{'entity1': 'NLR levels', 'relationship': 'hi...
2  487  The binary logistic regression analysis reveal...  [{'entity1': 'NLR exceeding the cutoff value',...
3  488  Consistent with our findings, a study by Sang ...  [{'entity1': 'NLR', 'relationship': 'associati...
4  489  PLR, another inflammatory marker based on comp...  [{'entity1': 'PLR', 'relationship': 'marker', ...
5  490  In our research, we observed that a PLR of 144...  [{'entity1': 'PLR of 144.7', 'relationship': '...
2024-04-05 02:27:31,283 - INFO - root - Successfully saved to dataframe!
2024-04-05 02:27:31,289 - INFO - root - Processing chunks 6/7
2024-04-05 02:27:49,169 - INFO - httpx - HTTP Request: POST https://api.anthropic.com/v1/complete "HTTP/1.1 200 OK"
2024-04-05 02:27:49,171 - INFO - root - Prediction:  Here are the samples extracted from the given article:

<sample>
{
  "input": "Insulin resistance (IR) is known to be characteristic of type 2 diabetes mellitus, and is regarded as an important mechanism in disease pathogenesis.",
  "output": [
    {
      "entity1": "Insulin resistance",
      "relationship": "characteristic",
      "entity2": "Type 2 diabetes mellitus"
    },
    {
      "entity1": "Insulin resistance",
      "relationship": "mechanism",
      "entity2": "disease pathogenesis"
    }
  ]
}
</sample>

<sample>
{
  "input": "One of the key pathogenetic mechanisms of IR progression is impaired free fatty acid (FFA) metabolism.",
  "output": [
    {
      "entity1": "pathogenesis",
      "relationship": "progression",
      "entity2": "impaired free fatty acid metabolism"  
    }
  ]
}
</sample>

<sample>
{
  "input": "Plasminogen-activator inhibitor 1 (PAI-1) and key inflammation markers, ie, interleukin 6 (IL-6) and C-reactive protein (CRP), also play a role.",
  "output": [
    {
      "entity1": "Plasminogen-activator inhibitor 1",
      "relationship": "role",
      "entity2": "Insulin resistance"
    },
    {
      "entity1": "Interleukin 6",
      "relationship": "role", 
      "entity2": "Insulin resistance"
    },
    {
      "entity1": "C-reactive protein", 
      "relationship": "role",
      "entity2": "Insulin resistance"
    }
  ]
}
</sample>

<sample>
{
  "input": "Among proinflammatory cytokines contributing to IR development, the role of interleukin (IL)-6, which has autocrine and paracrine properties and is involved in insulin reception and free fatty acid (FFA) metabolism regulation, has been extensively studied.",
  "output": [
    {
      "entity1": "Interleukin 6",
      "relationship": "contributing",
      "entity2": "Insulin resistance development"
    },
    {
      "entity1": "Interleukin 6",
      "relationship": "involved",
      "entity2": "insulin reception"
    },
    {
      "entity1": "Interleukin 6",
      "relationship": "involved", 
      "entity2": "free fatty acid metabolism regulation"
    }
  ]
}
</sample>
2024-04-05 02:27:49,173 - INFO - root - Processed Output: [{'input': 'Insulin resistance (IR) is known to be characteristic of type 2 diabetes mellitus, and is regarded as an important mechanism in disease pathogenesis.', 'output': [{'entity1': 'Insulin resistance', 'relationship': 'characteristic', 'entity2': 'Type 2 diabetes mellitus'}, {'entity1': 'Insulin resistance', 'relationship': 'mechanism', 'entity2': 'disease pathogenesis'}]}, {'input': 'One of the key pathogenetic mechanisms of IR progression is impaired free fatty acid (FFA) metabolism.', 'output': [{'entity1': 'pathogenesis', 'relationship': 'progression', 'entity2': 'impaired free fatty acid metabolism'}]}, {'input': 'Plasminogen-activator inhibitor 1 (PAI-1) and key inflammation markers, ie, interleukin 6 (IL-6) and C-reactive protein (CRP), also play a role.', 'output': [{'entity1': 'Plasminogen-activator inhibitor 1', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'Interleukin 6', 'relationship': 'role', 'entity2': 'Insulin resistance'}, {'entity1': 'C-reactive protein', 'relationship': 'role', 'entity2': 'Insulin resistance'}]}, {'input': 'Among proinflammatory cytokines contributing to IR development, the role of interleukin (IL)-6, which has autocrine and paracrine properties and is involved in insulin reception and free fatty acid (FFA) metabolism regulation, has been extensively studied.', 'output': [{'entity1': 'Interleukin 6', 'relationship': 'contributing', 'entity2': 'Insulin resistance development'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'insulin reception'}, {'entity1': 'Interleukin 6', 'relationship': 'involved', 'entity2': 'free fatty acid metabolism regulation'}]}]
2024-04-05 02:27:49,185 - INFO - root - New Rows:     id                                              input                                             output
0  491  Insulin resistance (IR) is known to be charact...  [{'entity1': 'Insulin resistance', 'relationsh...
1  492  One of the key pathogenetic mechanisms of IR p...  [{'entity1': 'pathogenesis', 'relationship': '...
2  493  Plasminogen-activator inhibitor 1 (PAI-1) and ...  [{'entity1': 'Plasminogen-activator inhibitor ...
3  494  Among proinflammatory cytokines contributing t...  [{'entity1': 'Interleukin 6', 'relationship': ...
2024-04-05 02:27:49,193 - INFO - root - Successfully saved to dataframe!
2024-04-05 02:27:49,200 - INFO - root - Processing chunks 7/7
2024-04-05 02:27:59,507 - INFO - httpx - HTTP Request: POST https://api.anthropic.com/v1/complete "HTTP/1.1 200 OK"
2024-04-05 02:27:59,509 - INFO - root - Prediction:  Here are some samples extracted from the given article:

<sample>
{
    "input": "The role of the hematological inflammatory index and systemic immuno-inflammation index in acute cholecystitis",
    "output": [
        {
            "entity1": "hematological inflammatory index",
            "relationship": "role", 
            "entity2": "acute cholecystitis"
        },
        {
            "entity1": "systemic immuno-inflammation index", 
            "relationship": "role",
            "entity2": "acute cholecystitis"
        }
    ]
}
</sample>

<sample>
{
    "input": "Predicting immunoglobulin resistance in Kawasaki disease: an assessment of neutrophil to lymphocyte platelet ratio",
    "output": [
        {
            "entity1": "neutrophil to lymphocyte platelet ratio",
            "relationship": "assessment", 
            "entity2": "Predicting immunoglobulin resistance in Kawasaki disease"
        }
    ]
}
</sample>

<sample>
{
    "input": "haematological ratios as risk factor for acute kidney injury in patients suspected of an infection at the emergency department",
    "output": [
        {
            "entity1": "haematological ratios",
            "relationship": "risk factor", 
            "entity2": "acute kidney injury" 
        }
    ]
}
</sample>

<sample>
{
    "input": "Role of leukocytes and systemic inflammation indexes (NLR, PLR, MLP, dNLR, NLPR, AISI, SIR-I, and SII) on admission predicts in-hospital mortality in non-elderly and elderly COVID-19 patients",
    "output": [
        {
            "entity1": "leukocytes and systemic inflammation indexes",
            "relationship": "predicts", 
            "entity2": "in-hospital mortality in non-elderly and elderly COVID-19 patients"
        }
    ]
}  
</sample>
2024-04-05 02:27:59,510 - INFO - root - Processed Output: [{'input': 'The role of the hematological inflammatory index and systemic immuno-inflammation index in acute cholecystitis', 'output': [{'entity1': 'hematological inflammatory index', 'relationship': 'role', 'entity2': 'acute cholecystitis'}, {'entity1': 'systemic immuno-inflammation index', 'relationship': 'role', 'entity2': 'acute cholecystitis'}]}, {'input': 'Predicting immunoglobulin resistance in Kawasaki disease: an assessment of neutrophil to lymphocyte platelet ratio', 'output': [{'entity1': 'neutrophil to lymphocyte platelet ratio', 'relationship': 'assessment', 'entity2': 'Predicting immunoglobulin resistance in Kawasaki disease'}]}, {'input': 'haematological ratios as risk factor for acute kidney injury in patients suspected of an infection at the emergency department', 'output': [{'entity1': 'haematological ratios', 'relationship': 'risk factor', 'entity2': 'acute kidney injury'}]}, {'input': 'Role of leukocytes and systemic inflammation indexes (NLR, PLR, MLP, dNLR, NLPR, AISI, SIR-I, and SII) on admission predicts in-hospital mortality in non-elderly and elderly COVID-19 patients', 'output': [{'entity1': 'leukocytes and systemic inflammation indexes', 'relationship': 'predicts', 'entity2': 'in-hospital mortality in non-elderly and elderly COVID-19 patients'}]}]
2024-04-05 02:27:59,520 - INFO - root - New Rows:     id                                              input                                             output
0  495  The role of the hematological inflammatory ind...  [{'entity1': 'hematological inflammatory index...
1  496  Predicting immunoglobulin resistance in Kawasa...  [{'entity1': 'neutrophil to lymphocyte platele...
2  497  haematological ratios as risk factor for acute...  [{'entity1': 'haematological ratios', 'relatio...
3  498  Role of leukocytes and systemic inflammation i...  [{'entity1': 'leukocytes and systemic inflamma...
2024-04-05 02:27:59,530 - INFO - root - Successfully saved to dataframe!
2024-04-05 02:27:59,530 - INFO - root - Successfully generated training data for file 0!
2024-04-05 02:27:59,531 - INFO - root - Processing File: 2
2024-04-05 02:27:59,533 - INFO - root - Successfully chunked the document!
2024-04-05 02:27:59,539 - INFO - root - Processing chunks 1/14
2024-04-05 02:28:21,119 - INFO - httpx - HTTP Request: POST https://api.anthropic.com/v1/complete "HTTP/1.1 200 OK"
2024-04-05 02:28:21,121 - INFO - root - Prediction:  Here are 5 sample training data extracted from the given article:

<sample>
{'input': 'Inflammatory  mechanisms  are  part  of  the  normal  body’s  defense  against  aggressions,  however,  when  they  last  for 
prolonged periods of time (months to years), they can induce a chronic inflammatory state that can be detrimental to the 
organism.',
'output': [{'entity1': 'Inflammatory mechanisms', 'relationship': 'part of', 'entity2': 'normal body’s defense'}, 
           {'entity1': 'Inflammatory mechanisms', 'relationship': 'induce', 'entity2': 'chronic inflammatory state'},
           {'entity1': 'chronic inflammatory state', 'relationship': 'detrimental to', 'entity2': 'organism'}]}
</sample>

<sample>
{'input': 'Besides the 
context  of  auto-immune  disorders,  some  of  the  reasons  that  can  perpetuate  a  low-grade  inflammation  could  be:  (i)  the 
organism’s inability to eliminate infectious agents such as bacteria, viruses or parasites, (ii) its prolonged exposure to low 
levels of chemicals, biochemicals or irritants,', 
'output': [{'entity1': 'auto-immune disorders', 'relationship': 'perpetuate', 'entity2': 'low-grade inflammation'},
           {'entity1': 'infectious agents', 'relationship': 'eliminate', 'entity2': 'organism'}, 
           {'entity1': 'chemicals, biochemicals or irritants', 'relationship': 'exposure to', 'entity2': 'organism'}]}
</sample>

<sample>
{'input': 'If  those  triggers  are  maintained  over  a  long  period  of  time,  they  can  lead  to  chronic  inflammatory-related 
diseases  that  can  involve  many  other  organs  and  tissue  of  the  body  like  the  gut,  driving  inflammatory  bowel  diseases 
(IBD);',
'output': [{'entity1': 'triggers', 'relationship': 'lead to', 'entity2': 'chronic inflammatory-related diseases'}, 
           {'entity1': 'chronic inflammatory-related diseases', 'relationship': 'involve', 'entity2': 'organs and tissue'},
           {'entity1': 'inflammatory-related diseases', 'relationship': 'driving', 'entity2': 'inflammatory bowel diseases'}]}
</sample>

<sample>
{'input': 'the  cardio-vascular  system  (stroke,  atherosclerosis);  the  brain  (depression,  neurodegenerative  diseases);  the 
immune system (auto-immune diseases and cancer); the endocrine-metabolic system (diabetes and obesity)',
'output': [{'entity1': 'chronic inflammation', 'relationship': 'related to', 'entity2': 'cardiovascular system disorders'},
           {'entity1': 'chronic inflammation', 'relationship': 'related to', 'entity2': 'brain disorders'},
           {'entity1': 'chronic inflammation', 'relationship': 'related to', 'entity2': 'immune system disorders'},
           {'entity1': 'chronic inflammation', 'relationship': 'related to', 'entity2': 'endocrine-metabolic system disorders'}]}  
</sample>

<sample>
{'input': 'In this regard, Micro-immunotherapy (MI) might be a promising therapeutic strategy. MI employs low doses (LD) 
and ultra-low doses (ULD) of immune regulators in their formulations.',
'output': [{'entity1': 'Micro-immunotherapy', 'relationship': 'promising strategy for', 'entity2': 'therapy'},
           {'entity1': 'Micro-immunotherapy', 'relationship': 'employs', 'entity2': 'low doses of immune regulators'},
           {'entity1': 'Micro-immunotherapy', 'relationship': 'employs', 'entity2': 'ultra-low doses of immune regulators'}]}
</sample>
2024-04-05 02:28:21,123 - INFO - root - Processed Output: [{'input': 'Inflammatory  mechanisms  are  part  of  the  normal  body’s  defense  against  aggressions,  however,  when  they  last  for prolonged periods of time (months to years), they can induce a chronic inflammatory state that can be detrimental to the organism.', 'output': [{'entity1': 'Inflammatory mechanisms', 'relationship': 'part of', 'entity2': 'normal body’s defense'}, {'entity1': 'Inflammatory mechanisms', 'relationship': 'induce', 'entity2': 'chronic inflammatory state'}, {'entity1': 'chronic inflammatory state', 'relationship': 'detrimental to', 'entity2': 'organism'}]}, {'input': 'Besides the context  of  auto-immune  disorders,  some  of  the  reasons  that  can  perpetuate  a  low-grade  inflammation  could  be:  (i)  the organism’s inability to eliminate infectious agents such as bacteria, viruses or parasites, (ii) its prolonged exposure to low levels of chemicals, biochemicals or irritants,', 'output': [{'entity1': 'auto-immune disorders', 'relationship': 'perpetuate', 'entity2': 'low-grade inflammation'}, {'entity1': 'infectious agents', 'relationship': 'eliminate', 'entity2': 'organism'}, {'entity1': 'chemicals, biochemicals or irritants', 'relationship': 'exposure to', 'entity2': 'organism'}]}, {'input': 'If  those  triggers  are  maintained  over  a  long  period  of  time,  they  can  lead  to  chronic  inflammatory-related diseases  that  can  involve  many  other  organs  and  tissue  of  the  body  like  the  gut,  driving  inflammatory  bowel  diseases (IBD);', 'output': [{'entity1': 'triggers', 'relationship': 'lead to', 'entity2': 'chronic inflammatory-related diseases'}, {'entity1': 'chronic inflammatory-related diseases', 'relationship': 'involve', 'entity2': 'organs and tissue'}, {'entity1': 'inflammatory-related diseases', 'relationship': 'driving', 'entity2': 'inflammatory bowel diseases'}]}, {'input': 'the  cardio-vascular  system  (stroke,  atherosclerosis);  the  brain  (depression,  neurodegenerative  diseases);  the immune system (auto-immune diseases and cancer); the endocrine-metabolic system (diabetes and obesity)', 'output': [{'entity1': 'chronic inflammation', 'relationship': 'related to', 'entity2': 'cardiovascular system disorders'}, {'entity1': 'chronic inflammation', 'relationship': 'related to', 'entity2': 'brain disorders'}, {'entity1': 'chronic inflammation', 'relationship': 'related to', 'entity2': 'immune system disorders'}, {'entity1': 'chronic inflammation', 'relationship': 'related to', 'entity2': 'endocrine-metabolic system disorders'}]}, {'input': 'In this regard, Micro-immunotherapy (MI) might be a promising therapeutic strategy. MI employs low doses (LD) and ultra-low doses (ULD) of immune regulators in their formulations.', 'output': [{'entity1': 'Micro-immunotherapy', 'relationship': 'promising strategy for', 'entity2': 'therapy'}, {'entity1': 'Micro-immunotherapy', 'relationship': 'employs', 'entity2': 'low doses of immune regulators'}, {'entity1': 'Micro-immunotherapy', 'relationship': 'employs', 'entity2': 'ultra-low doses of immune regulators'}]}]
2024-04-05 02:28:21,137 - INFO - root - New Rows:     id                                              input                                             output
0  499  Inflammatory  mechanisms  are  part  of  the  ...  [{'entity1': 'Inflammatory mechanisms', 'relat...
1  500  Besides the context  of  auto-immune  disorder...  [{'entity1': 'auto-immune disorders', 'relatio...
2  501  If  those  triggers  are  maintained  over  a ...  [{'entity1': 'triggers', 'relationship': 'lead...
3  502  the  cardio-vascular  system  (stroke,  athero...  [{'entity1': 'chronic inflammation', 'relation...
4  503  In this regard, Micro-immunotherapy (MI) might...  [{'entity1': 'Micro-immunotherapy', 'relations...
2024-04-05 02:28:21,146 - INFO - root - Successfully saved to dataframe!
2024-04-05 02:28:21,153 - INFO - root - Processing chunks 2/14
2024-04-05 02:29:08,735 - INFO - httpx - HTTP Request: POST https://api.anthropic.com/v1/complete "HTTP/1.1 200 OK"
2024-04-05 02:29:08,737 - INFO - root - Prediction:  Here are the samples extracted from the given article:

<sample>
{
    "input": "Numerous treatment strategies have been employed in order to reduce inflammation and immunotherapies are one of 
them.  For  instance,  the  use  of  cytokine-based  therapies  has  been  reported  in  the  management  of  sepsis,  diabetes,  or 
cardiovascular  diseases  with  quite  promising  results.",
    "output": [
        {
            "entity1": "treatment strategies",
            "relationship": "employed",
            "entity2": "reduce inflammation"
        },
        {
            "entity1": "immunotherapies", 
            "relationship": "reduce",
            "entity2": "inflammation"
        },
        {
            "entity1": "cytokine-based therapies",
            "relationship": "reported", 
            "entity2": "management of sepsis, diabetes, cardiovascular diseases"  
        }
    ]
}
</sample>

<sample>
{
    "input": "However,  unwanted  side  effects  still  remain,  probably  due  to  the 
cytokines or immune factors dosages employed.",
    "output": [
        {
            "entity1": "unwanted side effects",
            "relationship": "remain",
            "entity2": "cytokines or immune factors dosages"  
        }
    ]
}
</sample>

<sample>
{
    "input": "A therapeutic approach that includes micro-immunotherapy (MI) could 
thus be of great interest in order to face such concerns.",
    "output": [
        {
            "entity1": "A therapeutic approach",
            "relationship": "includes",
            "entity2": "micro-immunotherapy"
        },
        {
            "entity1": "micro-immunotherapy",
            "relationship": "interest",
            "entity2": "face such concerns"
        }
    ]
}
</sample>

<sample>
{
    "input": "Indeed, MI medicines (MIM) are immune-factor-based medicines, 
which formulations either encompass a sole active substance (unitary preparations; referred to as u-MIM) or a distinctive 
combination of several ingredients (complex MIM; referred to as c-MIM).",
    "output": [
        {
            "entity1": "MI medicines", 
            "relationship": "are",
            "entity2": "immune-factor-based medicines"
        },
        {
            "entity1": "formulations",
            "relationship": "encompass",
            "entity2": "a sole active substance" 
        },
        {
            "entity1": "formulations", 
            "relationship": "encompass",
            "entity2": "a distinctive combination of several ingredients"
        }
    ]
}
</sample>

<sample>
{
    "input": "These medicines are manufactured in the form 
of sucrose-lactose pillules impregnated with the corresponding active ingredients, for oromucosal administration, and are 
intended  to  be  taken  in  a  fasted  state.",
    "output": [
        {
            "entity1": "These medicines",
            "relationship": "manufactured",
            "entity2": "sucrose-lactose pillules"
        },
        {
            "entity1": "sucrose-lactose pillules",
            "relationship": "impregnated",
            "entity2": "active ingredients"
        },
        {
            "entity1": "These medicines",
            "relationship": "intended",
            "entity2": "oromucosal administration"  
        } 
    ]
}
</sample>

<sample>
{
    "input": "In  this  manner,  the  active  substances  can  reach  the  oral-pharyngeal  mucosal 
immune system,2 as well as the mucosal immune system of the gastrointestinal (GI) tract, with their associated lymphoid 
tissues and cell populations of the innate and adaptative immune responses.",
    "output": [
        {
            "entity1": "the active substances",
            "relationship": "reach",
            "entity2": "oral-pharyngeal mucosal immune system"
        },
        {
            "entity1": "the active substances",
            "relationship": "reach",
            "entity2": "mucosal immune system"
        }
    ]
}  
</sample>

<sample>
{
    "input": "This route of administration will, in turn, 
elicit systemic and local effects, as we could observe in previous published preclinical in vivo studies.",
    "output": [
        {
            "entity1": "This route of administration",
            "relationship": "elicit",
            "entity2": "systemic and local effects"
        }
    ]
}
</sample>

<sample>
{
    "input": "Through their exclusive preparation, MIM aim at gently modulating the expression and the related signaling pathways 
of cytokines and immune factors by providing to the organism these molecules at low doses (LD) and ultra-low doses 
(ULD) (Figure 1).",
    "output": [
        {
            "entity1": "MIM",
            "relationship": "aim", 
            "entity2": "gently modulating the expression and the related signaling pathways" 
        },
        {
            "entity1": "MIM",
            "relationship": "providing",
            "entity2": "the organism these molecules at low doses and ultra-low doses"
        }
    ]
}
</sample>

<sample>
{
    "input": "LD of 
bioactive  molecules  (ranging  from  3  to  5  CH)  are  used  in  MI  formulations  to  mimic  the  low  doses  occurring  in  the 
organism,7,8 and are employed to induce their own biological effects, stimulating their functions (Figure 1, green part).", 
    "output": [
        {
            "entity1": "LD of bioactive molecules",
            "relationship": "used",
            "entity2": "MI formulations"
        },
        {
            "entity1": "LD of bioactive molecules ", 
            "relationship": "employed",
            "entity2": "induce their own biological effects"
        },
        {
            "entity1": "LD of bioactive molecules",
            "relationship": "employed", 
            "entity2": "stimulating their functions" 
        }
    ]
}
</sample>
2024-04-05 02:29:08,739 - INFO - root - Processed Output: [{'input': 'Numerous treatment strategies have been employed in order to reduce inflammation and immunotherapies are one of them.  For  instance,  the  use  of  cytokine-based  therapies  has  been  reported  in  the  management  of  sepsis,  diabetes,  or cardiovascular  diseases  with  quite  promising  results.', 'output': [{'entity1': 'treatment strategies', 'relationship': 'employed', 'entity2': 'reduce inflammation'}, {'entity1': 'immunotherapies', 'relationship': 'reduce', 'entity2': 'inflammation'}, {'entity1': 'cytokine-based therapies', 'relationship': 'reported', 'entity2': 'management of sepsis, diabetes, cardiovascular diseases'}]}, {'input': 'However,  unwanted  side  effects  still  remain,  probably  due  to  the cytokines or immune factors dosages employed.', 'output': [{'entity1': 'unwanted side effects', 'relationship': 'remain', 'entity2': 'cytokines or immune factors dosages'}]}, {'input': 'A therapeutic approach that includes micro-immunotherapy (MI) could thus be of great interest in order to face such concerns.', 'output': [{'entity1': 'A therapeutic approach', 'relationship': 'includes', 'entity2': 'micro-immunotherapy'}, {'entity1': 'micro-immunotherapy', 'relationship': 'interest', 'entity2': 'face such concerns'}]}, {'input': 'Indeed, MI medicines (MIM) are immune-factor-based medicines, which formulations either encompass a sole active substance (unitary preparations; referred to as u-MIM) or a distinctive combination of several ingredients (complex MIM; referred to as c-MIM).', 'output': [{'entity1': 'MI medicines', 'relationship': 'are', 'entity2': 'immune-factor-based medicines'}, {'entity1': 'formulations', 'relationship': 'encompass', 'entity2': 'a sole active substance'}, {'entity1': 'formulations', 'relationship': 'encompass', 'entity2': 'a distinctive combination of several ingredients'}]}, {'input': 'These medicines are manufactured in the form of sucrose-lactose pillules impregnated with the corresponding active ingredients, for oromucosal administration, and are intended  to  be  taken  in  a  fasted  state.', 'output': [{'entity1': 'These medicines', 'relationship': 'manufactured', 'entity2': 'sucrose-lactose pillules'}, {'entity1': 'sucrose-lactose pillules', 'relationship': 'impregnated', 'entity2': 'active ingredients'}, {'entity1': 'These medicines', 'relationship': 'intended', 'entity2': 'oromucosal administration'}]}, {'input': 'In  this  manner,  the  active  substances  can  reach  the  oral-pharyngeal  mucosal immune system,2 as well as the mucosal immune system of the gastrointestinal (GI) tract, with their associated lymphoid tissues and cell populations of the innate and adaptative immune responses.', 'output': [{'entity1': 'the active substances', 'relationship': 'reach', 'entity2': 'oral-pharyngeal mucosal immune system'}, {'entity1': 'the active substances', 'relationship': 'reach', 'entity2': 'mucosal immune system'}]}, {'input': 'This route of administration will, in turn, elicit systemic and local effects, as we could observe in previous published preclinical in vivo studies.', 'output': [{'entity1': 'This route of administration', 'relationship': 'elicit', 'entity2': 'systemic and local effects'}]}, {'input': 'Through their exclusive preparation, MIM aim at gently modulating the expression and the related signaling pathways of cytokines and immune factors by providing to the organism these molecules at low doses (LD) and ultra-low doses (ULD) (Figure 1).', 'output': [{'entity1': 'MIM', 'relationship': 'aim', 'entity2': 'gently modulating the expression and the related signaling pathways'}, {'entity1': 'MIM', 'relationship': 'providing', 'entity2': 'the organism these molecules at low doses and ultra-low doses'}]}, {'input': 'LD of bioactive  molecules  (ranging  from  3  to  5  CH)  are  used  in  MI  formulations  to  mimic  the  low  doses  occurring  in  the organism,7,8 and are employed to induce their own biological effects, stimulating their functions (Figure 1, green part).', 'output': [{'entity1': 'LD of bioactive molecules', 'relationship': 'used', 'entity2': 'MI formulations'}, {'entity1': 'LD of bioactive molecules ', 'relationship': 'employed', 'entity2': 'induce their own biological effects'}, {'entity1': 'LD of bioactive molecules', 'relationship': 'employed', 'entity2': 'stimulating their functions'}]}]
2024-04-05 02:29:08,753 - INFO - root - New Rows:     id                                              input                                             output
0  504  Numerous treatment strategies have been employ...  [{'entity1': 'treatment strategies', 'relation...
1  505  However,  unwanted  side  effects  still  rema...  [{'entity1': 'unwanted side effects', 'relatio...
2  506  A therapeutic approach that includes micro-imm...  [{'entity1': 'A therapeutic approach', 'relati...
3  507  Indeed, MI medicines (MIM) are immune-factor-b...  [{'entity1': 'MI medicines', 'relationship': '...
4  508  These medicines are manufactured in the form o...  [{'entity1': 'These medicines', 'relationship'...
5  509  In  this  manner,  the  active  substances  ca...  [{'entity1': 'the active substances', 'relatio...
6  510  This route of administration will, in turn, el...  [{'entity1': 'This route of administration', '...
7  511  Through their exclusive preparation, MIM aim a...  [{'entity1': 'MIM', 'relationship': 'aim', 'en...
8  512  LD of bioactive  molecules  (ranging  from  3 ...  [{'entity1': 'LD of bioactive molecules', 'rel...
2024-04-05 02:29:08,762 - INFO - root - Successfully saved to dataframe!
2024-04-05 02:29:08,768 - INFO - root - Processing chunks 3/14
2024-04-05 02:30:26,459 - INFO - httpx - HTTP Request: POST https://api.anthropic.com/v1/complete "HTTP/1.1 200 OK"
2024-04-05 02:30:26,462 - INFO - root - Prediction:  Here are the samples extracted from the given article:

<sample>
{'input': 'Recent literature delineated the importance of IL-8 and IL-10 in the molecular mechanisms driving GI inflammatory 
diseases.14,15 The fact that c-MIM-1 includes ULD of IL-8 and LD of IL-10 in its formulation thus motivated the choice 
of assessing the cellular effects of this medicine in an in vitro model of intestinal inflammation (Figure 2B, red box).',
'output': [{'entity1': 'IL-8', 'relationship': 'importance', 'entity2': 'molecular mechanisms driving GI inflammatory diseases'}, 
           {'entity1': 'IL-10', 'relationship': 'importance', 'entity2': 'molecular mechanisms driving GI inflammatory diseases'},
           {'entity1': 'c-MIM-1', 'relationship': 'includes', 'entity2': 'ULD of IL-8'}, 
           {'entity1': 'c-MIM-1', 'relationship': 'includes', 'entity2': 'LD of IL-10'},
           {'entity1': 'c-MIM-1', 'relationship': 'motivated', 'entity2': 'assessing cellular effects in intestinal inflammation model'}]}
</sample>

<sample>
{'input': 'In a more general approach, c-MIM-2 and c-MIM-3 have been investigated in vitro, on the immune axis in different 
cell types and inflamed experimental contexts (Figure 2B, blue box).', 
'output': [{'entity1': 'c-MIM-2', 'relationship': 'investigated', 'entity2': 'in vitro'}, 
           {'entity1': 'c-MIM-3', 'relationship': 'investigated', 'entity2': 'in vitro'},
           {'entity1': 'c-MIM-2', 'relationship': 'investigated', 'entity2': 'immune axis'},
           {'entity1': 'c-MIM-3', 'relationship': 'investigated', 'entity2': 'immune axis'}]}
</sample>

<sample>
{'input': 'These two formulations employ ULD of IL-1β and 
TNF-α in association with ULD of PGE2, or ULD of IL-6, IL-13, and OSM, and LD of IL-10, or LD of TGF-β and IL- 
1Ra.',
'output': [{'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'ULD of IL-1β'}, 
           {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'ULD of TNF-α'},
           {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'ULD of PGE2'},
           {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'ULD of IL-6'},
           {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'ULD of IL-13'},
           {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'ULD of OSM'},
           {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'LD of IL-10'},
           {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'LD of TGF-β'}, 
           {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'LD of IL-1Ra'}]}
</sample>

<sample>
{'input': 'Numerous publications, nicely put together in the review from Tsuge et al indeed reported the major role played by 
PGE2 in the mediation of inflammation and immune diseases, notably through its implication in mechanisms related to 
Th1 differentiation, and Th1/Th17/Th22 signaling.16',
'output': [{'entity1': 'PGE2', 'relationship': 'role', 'entity2': 'mediation of inflammation and immune diseases'},
           {'entity1': 'PGE2', 'relationship': 'implication', 'entity2': 'mechanisms related to Th1 differentiation'}, 
           {'entity1': 'PGE2', 'relationship': 'implication', 'entity2': 'Th1/Th17/Th22 signaling'}]}
</sample>

<sample>
{'input': 'In the context of immunity, IL-10 is produced by a broad type of 
myeloid  and  lymphoid  cells  during  infections,  and  suppresses  macrophages  and  dendritic  cells  functions,  thereby 
impeding Th1 and  Th2  effector responses.17',
'output': [{'entity1': 'IL-10', 'relationship': 'produced by', 'entity2': 'myeloid and lymphoid cells'},
           {'entity1': 'IL-10', 'relationship': 'suppresses', 'entity2': 'macrophages and dendritic cells functions'},
           {'entity1': 'IL-10', 'relationship': 'impeding', 'entity2': 'Th1 and Th2 effector responses'}]}  
</sample>

<sample>
{'input': 'In immune effector cell types, and  in a wide  range of  established models 
of chronic inflammation, IL-10 is reported to play a central role in the regulation of homeostasis.18', 
'output': [{'entity1': 'IL-10', 'relationship': 'role', 'entity2': 'regulation of homeostasis'}]}
</sample>  

<sample>  
{'input': 'On another side, TGF- 
β is  important  in  maintaining the  T cell  tolerance to  self  or  innocuous  environmental  antigens.19',
'output': [{'entity1': 'TGF-β', 'relationship': 'important', 'entity2': 'maintaining T cell tolerance'}]}
</sample>

<sample> 
{'input': 'IL-1 is  known  for  its 
crucial  involvement  in  the  onset  and/or  the  etiopathogenesis  of  several  inflammatory-mediated  diseases.',  
'output': [{'entity1': 'IL-1', 'relationship': 'involvement', 'entity2': 'onset of inflammatory diseases'},
           {'entity1': 'IL-1', 'relationship': 'involvement', 'entity2': 'etiopathogenesis of inflammatory diseases'}]}
</sample>

<sample>
{'input': 'Given its 
importance,  several  therapeutic  approaches  consisting  of  the  use  of  IL-Ra  have  been  used  in  clinical  practice  to  block 
the activity of IL-1.20',
'output': [{'entity1': 'IL-Ra', 'relationship': 'used', 'entity2': 'block IL-1 activity'}]} 
</sample>

<sample>  
{'input': 'OSM is a pleiotropic cytokine playing important roles  in a wide range of homeostatic functions 
(such as hematopoiesis, bone/fat turnover, liver regeneration) and, under chronic inflammatory diseases, it may play pro- 
inflammatory  roles,  depending  on  the  microenvironment  and  the  interested  tissue,  without  being  overexpressed  at 
systemic  levels.21',
'output': [{'entity1': 'OSM', 'relationship': 'roles', 'entity2': 'homeostatic functions'}, 
           {'entity1': 'OSM', 'relationship': 'roles', 'entity2': 'inflammatory diseases'}]}
</sample>

<sample>
{'input': 'IL-6  is  also  a  pleiotropic  cytokine  playing  important  roles  in  hematopoiesis,  bone  metabolism 
embryonic  development,  immunity,  and  host  responses.',
'output': [{'entity1': 'IL-6', 'relationship': 'roles', 'entity2': 'hematopoiesis'},
           {'entity1': 'IL-6', 'relationship': 'roles', 'entity2': 'bone metabolism'},
           {'entity1': 'IL-6', 'relationship': 'roles', 'entity2': 'embryonic development'},
           {'entity1': 'IL-6', 'relationship': 'roles', 'entity2': 'immunity'}, 
           {'entity1': 'IL-6', 'relationship': 'roles', 'entity2': 'host responses'}]}
</sample> 

<sample>   
{'input': 'Its  expression  is  finely  regulated  at  multiple  levels,  and  when 
a dysregulated and persistent IL-6 expression occurs, it may lead to the development of various inflammatory-mediated 
diseases.22,23',  
'output': [{'entity1': 'dysregulated IL-6 expression', 'relationship': 'lead to', 'entity2': 'inflammatory diseases'}]}
</sample>

<sample>
{'input': ' Similarly,  IL-13  is  known  to  exert  pleiotropic  effects  and  to  be  involved  in  inflammatory-mediated 
diseases.24',
'output': [{'entity1': 'IL-13', 'relationship': 'involved in', 'entity2': 'inflammatory diseases'}]}
</sample>

<sample> 
{'input': 'Finally, in the case of c-MIM-4, which employs ULD of both IL-6 and IL-12 in its formulation, as well as IL-4 at LD, 
one  of  the  goals  of  this  study  was  to  assess  its  effects  using  an  in  vitro  preclinical  model  of  neuronal  inflammation.',
'output': [{'entity1': 'c-MIM-4', 'relationship': 'employs', 'entity2': 'ULD of IL-6'}, 
           {'entity1': 'c-MIM-4', 'relationship': 'employs', 'entity2': 'ULD of IL-12'},  
           {'entity1': 'c-MIM-4', 'relationship': 'employs', 'entity2': 'LD of IL-4'},
           {'entity1': 'c-MIM-4', 'relationship': 'assess effects', 'entity2': 'neuronal inflammation model'}]}
</sample>

<sample>
{'input': 'The rationale behind the choice of the neuronal-inflammation context was supported by a rich 
bibliography,  illustrated  by  the  following  examples.', 
'output': [{'entity1': 'neuronal-inflammation context', 'relationship': 'supported by', 'entity2': 'bibliography'}]}
</sample>

<sample>  
{'input': 'For instance,  according  to  the  results  of  a  recent  meta-analysis, 
patients suffering from depressive symptoms express higher levels of IL-6.25',
'output': [{'entity1': 'depressive symptoms', 'relationship': 'associated with', 'entity2': 'higher IL-6 levels'}]}  
</sample>

<sample> 
{'input': 'Another study also reported that the IL-12 
serum  levels  of  patients  with  major  depression  were  significantly  higher  than  healthy  controls,  and  that  an  8-weeks 
treatment led to a reduction of these levels.26',  
'output': [{'entity1': 'major depression', 'relationship': 'associated with', 'entity2': 'higher IL-12 levels'}]}
</sample>

<sample>
{'input': 'On the other hand, it was suggested that IL-4 could modulate IL-1β-induced 
depressive behavior in rats, by inhibiting IL-1β-induced central glial activation and neurotransmitter alterations.27',
'output': [{'entity1': 'IL-4', 'relationship': 'modulate', 'entity2': 'IL-1β-induced depressive behavior'}, 
           {'entity1': 'IL-4', 'relationship': 'inhibiting', 'entity2': 'IL-1β-induced glial activation'},
           {'entity1': 'IL-4', 'relationship': 'inhibiting', 'entity2': 'IL-1β-induced neurotransmitter alterations'}]}
</sample>
2024-04-05 02:30:26,465 - INFO - root - Processed Output: [{'input': 'Recent literature delineated the importance of IL-8 and IL-10 in the molecular mechanisms driving GI inflammatory diseases.14,15 The fact that c-MIM-1 includes ULD of IL-8 and LD of IL-10 in its formulation thus motivated the choice of assessing the cellular effects of this medicine in an in vitro model of intestinal inflammation (Figure 2B, red box).', 'output': [{'entity1': 'IL-8', 'relationship': 'importance', 'entity2': 'molecular mechanisms driving GI inflammatory diseases'}, {'entity1': 'IL-10', 'relationship': 'importance', 'entity2': 'molecular mechanisms driving GI inflammatory diseases'}, {'entity1': 'c-MIM-1', 'relationship': 'includes', 'entity2': 'ULD of IL-8'}, {'entity1': 'c-MIM-1', 'relationship': 'includes', 'entity2': 'LD of IL-10'}, {'entity1': 'c-MIM-1', 'relationship': 'motivated', 'entity2': 'assessing cellular effects in intestinal inflammation model'}]}, {'input': 'In a more general approach, c-MIM-2 and c-MIM-3 have been investigated in vitro, on the immune axis in different cell types and inflamed experimental contexts (Figure 2B, blue box).', 'output': [{'entity1': 'c-MIM-2', 'relationship': 'investigated', 'entity2': 'in vitro'}, {'entity1': 'c-MIM-3', 'relationship': 'investigated', 'entity2': 'in vitro'}, {'entity1': 'c-MIM-2', 'relationship': 'investigated', 'entity2': 'immune axis'}, {'entity1': 'c-MIM-3', 'relationship': 'investigated', 'entity2': 'immune axis'}]}, {'input': 'These two formulations employ ULD of IL-1β and TNF-α in association with ULD of PGE2, or ULD of IL-6, IL-13, and OSM, and LD of IL-10, or LD of TGF-β and IL- 1Ra.', 'output': [{'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'ULD of IL-1β'}, {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'ULD of TNF-α'}, {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'ULD of PGE2'}, {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'ULD of IL-6'}, {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'ULD of IL-13'}, {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'ULD of OSM'}, {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'LD of IL-10'}, {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'LD of TGF-β'}, {'entity1': 'two formulations', 'relationship': 'employ', 'entity2': 'LD of IL-1Ra'}]}, {'input': 'Numerous publications, nicely put together in the review from Tsuge et al indeed reported the major role played by PGE2 in the mediation of inflammation and immune diseases, notably through its implication in mechanisms related to Th1 differentiation, and Th1/Th17/Th22 signaling.16', 'output': [{'entity1': 'PGE2', 'relationship': 'role', 'entity2': 'mediation of inflammation and immune diseases'}, {'entity1': 'PGE2', 'relationship': 'implication', 'entity2': 'mechanisms related to Th1 differentiation'}, {'entity1': 'PGE2', 'relationship': 'implication', 'entity2': 'Th1/Th17/Th22 signaling'}]}, {'input': 'In the context of immunity, IL-10 is produced by a broad type of myeloid  and  lymphoid  cells  during  infections,  and  suppresses  macrophages  and  dendritic  cells  functions,  thereby impeding Th1 and  Th2  effector responses.17', 'output': [{'entity1': 'IL-10', 'relationship': 'produced by', 'entity2': 'myeloid and lymphoid cells'}, {'entity1': 'IL-10', 'relationship': 'suppresses', 'entity2': 'macrophages and dendritic cells functions'}, {'entity1': 'IL-10', 'relationship': 'impeding', 'entity2': 'Th1 and Th2 effector responses'}]}, {'input': 'In immune effector cell types, and  in a wide  range of  established models of chronic inflammation, IL-10 is reported to play a central role in the regulation of homeostasis.18', 'output': [{'entity1': 'IL-10', 'relationship': 'role', 'entity2': 'regulation of homeostasis'}]}, {'input': 'On another side, TGF- β is  important  in  maintaining the  T cell  tolerance to  self  or  innocuous  environmental  antigens.19', 'output': [{'entity1': 'TGF-β', 'relationship': 'important', 'entity2': 'maintaining T cell tolerance'}]}, {'input': 'IL-1 is  known  for  its crucial  involvement  in  the  onset  and/or  the  etiopathogenesis  of  several  inflammatory-mediated  diseases.', 'output': [{'entity1': 'IL-1', 'relationship': 'involvement', 'entity2': 'onset of inflammatory diseases'}, {'entity1': 'IL-1', 'relationship': 'involvement', 'entity2': 'etiopathogenesis of inflammatory diseases'}]}, {'input': 'Given its importance,  several  therapeutic  approaches  consisting  of  the  use  of  IL-Ra  have  been  used  in  clinical  practice  to  block the activity of IL-1.20', 'output': [{'entity1': 'IL-Ra', 'relationship': 'used', 'entity2': 'block IL-1 activity'}]}, {'input': 'OSM is a pleiotropic cytokine playing important roles  in a wide range of homeostatic functions (such as hematopoiesis, bone/fat turnover, liver regeneration) and, under chronic inflammatory diseases, it may play pro- inflammatory  roles,  depending  on  the  microenvironment  and  the  interested  tissue,  without  being  overexpressed  at systemic  levels.21', 'output': [{'entity1': 'OSM', 'relationship': 'roles', 'entity2': 'homeostatic functions'}, {'entity1': 'OSM', 'relationship': 'roles', 'entity2': 'inflammatory diseases'}]}, {'input': 'IL-6  is  also  a  pleiotropic  cytokine  playing  important  roles  in  hematopoiesis,  bone  metabolism embryonic  development,  immunity,  and  host  responses.', 'output': [{'entity1': 'IL-6', 'relationship': 'roles', 'entity2': 'hematopoiesis'}, {'entity1': 'IL-6', 'relationship': 'roles', 'entity2': 'bone metabolism'}, {'entity1': 'IL-6', 'relationship': 'roles', 'entity2': 'embryonic development'}, {'entity1': 'IL-6', 'relationship': 'roles', 'entity2': 'immunity'}, {'entity1': 'IL-6', 'relationship': 'roles', 'entity2': 'host responses'}]}, {'input': 'Its  expression  is  finely  regulated  at  multiple  levels,  and  when a dysregulated and persistent IL-6 expression occurs, it may lead to the development of various inflammatory-mediated diseases.22,23', 'output': [{'entity1': 'dysregulated IL-6 expression', 'relationship': 'lead to', 'entity2': 'inflammatory diseases'}]}, {'input': ' Similarly,  IL-13  is  known  to  exert  pleiotropic  effects  and  to  be  involved  in  inflammatory-mediated diseases.24', 'output': [{'entity1': 'IL-13', 'relationship': 'involved in', 'entity2': 'inflammatory diseases'}]}, {'input': 'Finally, in the case of c-MIM-4, which employs ULD of both IL-6 and IL-12 in its formulation, as well as IL-4 at LD, one  of  the  goals  of  this  study  was  to  assess  its  effects  using  an  in  vitro  preclinical  model  of  neuronal  inflammation.', 'output': [{'entity1': 'c-MIM-4', 'relationship': 'employs', 'entity2': 'ULD of IL-6'}, {'entity1': 'c-MIM-4', 'relationship': 'employs', 'entity2': 'ULD of IL-12'}, {'entity1': 'c-MIM-4', 'relationship': 'employs', 'entity2': 'LD of IL-4'}, {'entity1': 'c-MIM-4', 'relationship': 'assess effects', 'entity2': 'neuronal inflammation model'}]}, {'input': 'The rationale behind the choice of the neuronal-inflammation context was supported by a rich bibliography,  illustrated  by  the  following  examples.', 'output': [{'entity1': 'neuronal-inflammation context', 'relationship': 'supported by', 'entity2': 'bibliography'}]}, {'input': 'For instance,  according  to  the  results  of  a  recent  meta-analysis, patients suffering from depressive symptoms express higher levels of IL-6.25', 'output': [{'entity1': 'depressive symptoms', 'relationship': 'associated with', 'entity2': 'higher IL-6 levels'}]}, {'input': 'Another study also reported that the IL-12 serum  levels  of  patients  with  major  depression  were  significantly  higher  than  healthy  controls,  and  that  an  8-weeks treatment led to a reduction of these levels.26', 'output': [{'entity1': 'major depression', 'relationship': 'associated with', 'entity2': 'higher IL-12 levels'}]}, {'input': 'On the other hand, it was suggested that IL-4 could modulate IL-1β-induced depressive behavior in rats, by inhibiting IL-1β-induced central glial activation and neurotransmitter alterations.27', 'output': [{'entity1': 'IL-4', 'relationship': 'modulate', 'entity2': 'IL-1β-induced depressive behavior'}, {'entity1': 'IL-4', 'relationship': 'inhibiting', 'entity2': 'IL-1β-induced glial activation'}, {'entity1': 'IL-4', 'relationship': 'inhibiting', 'entity2': 'IL-1β-induced neurotransmitter alterations'}]}]
2024-04-05 02:30:26,483 - INFO - root - New Rows:      id                                              input                                             output
0   513  Recent literature delineated the importance of...  [{'entity1': 'IL-8', 'relationship': 'importan...
1   514  In a more general approach, c-MIM-2 and c-MIM-...  [{'entity1': 'c-MIM-2', 'relationship': 'inves...
2   515  These two formulations employ ULD of IL-1β and...  [{'entity1': 'two formulations', 'relationship...
3   516  Numerous publications, nicely put together in ...  [{'entity1': 'PGE2', 'relationship': 'role', '...
4   517  In the context of immunity, IL-10 is produced ...  [{'entity1': 'IL-10', 'relationship': 'produce...
5   518  In immune effector cell types, and  in a wide ...  [{'entity1': 'IL-10', 'relationship': 'role', ...
6   519  On another side, TGF- β is  important  in  mai...  [{'entity1': 'TGF-β', 'relationship': 'importa...
7   520  IL-1 is  known  for  its crucial  involvement ...  [{'entity1': 'IL-1', 'relationship': 'involvem...
8   521  Given its importance,  several  therapeutic  a...  [{'entity1': 'IL-Ra', 'relationship': 'used', ...
9   522  OSM is a pleiotropic cytokine playing importan...  [{'entity1': 'OSM', 'relationship': 'roles', '...
10  523  IL-6  is  also  a  pleiotropic  cytokine  play...  [{'entity1': 'IL-6', 'relationship': 'roles', ...
11  524  Its  expression  is  finely  regulated  at  mu...  [{'entity1': 'dysregulated IL-6 expression', '...
12  525   Similarly,  IL-13  is  known  to  exert  plei...  [{'entity1': 'IL-13', 'relationship': 'involve...
13  526  Finally, in the case of c-MIM-4, which employs...  [{'entity1': 'c-MIM-4', 'relationship': 'emplo...
14  527  The rationale behind the choice of the neurona...  [{'entity1': 'neuronal-inflammation context', ...
15  528  For instance,  according  to  the  results  of...  [{'entity1': 'depressive symptoms', 'relations...
16  529  Another study also reported that the IL-12 ser...  [{'entity1': 'major depression', 'relationship...
17  530  On the other hand, it was suggested that IL-4 ...  [{'entity1': 'IL-4', 'relationship': 'modulate...
2024-04-05 02:30:26,493 - INFO - root - Successfully saved to dataframe!
2024-04-05 02:30:26,499 - INFO - root - Processing chunks 4/14
2024-04-05 02:31:33,325 - INFO - httpx - HTTP Request: POST https://api.anthropic.com/v1/complete "HTTP/1.1 200 OK"
2024-04-05 02:31:33,327 - INFO - root - Prediction:  Here are the samples extracted from the given article:

<sample>
{'input': 'Human peripheral blood mononuclear cells (PBMC) from healthy adult volunteer donors were isolated by centrifugation of venous blood on Ficoll-Hypaque density gradients (Amersham Pharmacia Biotech, Piscataway, NJ, USA).', 
'output': [{'entity1': 'Human peripheral blood mononuclear cells', 'relationship': 'isolated from', 'entity2': 'venous blood'},
           {'entity1': 'venous blood', 'relationship': 'centrifugation on', 'entity2': 'Ficoll-Hypaque density gradients'}]}
</sample>

<sample>
{'input': 'Cells (105/mL) were cultured in 24-well round-bottom plates in 2 mL of complete medium and stimulated with phytohemagglutinin (PHA) (5 μg/mL) for 48 hours.',
'output': [{'entity1': 'Cells', 'relationship': 'cultured in', 'entity2': '24-well round-bottom plates'}, 
           {'entity1': 'Cells', 'relationship': 'stimulated with', 'entity2': 'phytohemagglutinin'}]}
</sample>

<sample>
{'input': 'The SN were collected and stored at −80°C until use.',
'output': [{'entity1': 'The SN', 'relationship': 'collected and stored at', 'entity2': '-80°C'}]}  
</sample>

<sample>
{'input': 'Human Colonic Epithelial Cells (HCoEpiC) were purchased from Innoprot, Bizkaia, Spain.',
'output': [{'entity1': 'Human Colonic Epithelial Cells', 'relationship': 'purchased from', 'entity2': 'Innoprot, Bizkaia, Spain'}]}
</sample>

<sample>
{'input': 'The cells were seeded at the density of 5×105 cells in 24-well plate inserts whose diameter is 6.5 mm and the membrane area 0.3 cm2 and grown until tight confluence.',
'output': [{'entity1': 'The cells', 'relationship': 'seeded at', 'entity2': 'density of 5×105 cells'},
           {'entity1': 'The cells', 'relationship': 'grown until', 'entity2': 'tight confluence'}]}
</sample>

<sample>
{'input': 'The trans-epithelial resistance (TEER) measurements were obtained as Ω/cm2 and performed with a Millicell® ERS-2 device at different incubation times (24 hours and 72 hours), in the presence/absence of the PBMC SN, with/without c-MIM-4 or Veh. added 30 minutes before reading.', 
'output': [{'entity1': 'The trans-epithelial resistance measurements', 'relationship': 'obtained as', 'entity2': 'Ω/cm2'},
           {'entity1': 'The trans-epithelial resistance measurements', 'relationship': 'performed with', 'entity2': 'Millicell® ERS-2 device'}, 
           {'entity1': 'The trans-epithelial resistance measurements', 'relationship': 'performed at', 'entity2': 'different incubation times'},
           {'entity1': 'c-MIM-4', 'relationship': 'added', 'entity2': 'The trans-epithelial resistance measurements'},
           {'entity1': 'Veh.', 'relationship': 'added', 'entity2': 'The trans-epithelial resistance measurements'}]}
</sample>

<sample>
{'input': '10 mM of sodium caprate (C10) (Sigma-Aldrich, ref # C4151) was used as a positive control.', 
'output': [{'entity1': 'sodium caprate', 'relationship': 'used as', 'entity2': 'a positive control'}]}
</sample>

<sample>
{'input': 'HCoEpiC cells were treated with or without Veh. or c-MIM-1 for 24 h.',
'output': [{'entity1': 'HCoEpiC cells', 'relationship': 'treated with', 'entity2': 'Veh.'}, 
           {'entity1': 'HCoEpiC cells', 'relationship': 'treated with', 'entity2': 'c-MIM-1'}]}
</sample>  

<sample>
{'input': 'After that, 400 μL of human PBMC SN previously activated with PHA during 48 h was added to each well for 30 minutes.',
'output': [{'entity1': 'human PBMC SN', 'relationship': 'activated with', 'entity2': 'PHA'},
           {'entity1': 'human PBMC SN', 'relationship': 'added to', 'entity2': 'each well'}]}
</sample>

<sample>
{'input': 'For quantitative reverse transcriptase-PCR assays, total RNA (1 μg) was retrotranscribed using the iScript cDNA Synthesis Kit (Ref #1708891, Bio-Rad, Hercules, CA, USA) and the cDNA was analyzed by real-time PCR using the iQTM SYBR Green Supermix (Ref #1708880, Bio-Rad) and a CFX96 Real-time PCR Detection System (Bio-Rad).',
'output': [{'entity1': 'total RNA', 'relationship': 'retrotranscribed using', 'entity2': 'iScript cDNA Synthesis Kit'}, 
           {'entity1': 'the cDNA', 'relationship': 'analyzed by', 'entity2': 'real-time PCR'},
           {'entity1': 'real-time PCR', 'relationship': 'using', 'entity2': 'iQTM SYBR Green Supermix'},
           {'entity1': 'real-time PCR', 'relationship': 'using', 'entity2': 'CFX96 Real-time PCR Detection System'}]}
</sample>

<sample>
{'input': 'Claudin-1: F: 5’-AGG TCT GGC GAC ATT AGT GG-3’; R: 5’-CGT GGT GTT GGG TAA GAG GT-3’; GAPDH: F: 3’-TGG CAA AGT GGA GAT TGT TGC C-3’; R: 5’-AAG ATG GTG ATG GGC TTC CCG-3’.',
'output': [{'entity1': 'Claudin-1', 'relationship': 'F', 'entity2': '5’-AGG TCT GGC GAC ATT AGT GG-3’'}, 
           {'entity1': 'Claudin-1', 'relationship': 'R', 'entity2': '5’-CGT GGT GTT GGG TAA GAG GT-3’'},
           {'entity1': 'GAPDH', 'relationship': 'F', 'entity2': '3’-TGG CAA AGT GGA GAT TGT TGC C-3’'},
           {'entity1': 'GAPDH', 'relationship': 'R', 'entity2': '5’-AAG ATG GTG ATG GGC TTC CCG-3’'}]}
</sample>
            
<sample>             
{'input': 'The cells were washed with phosphate-buffered saline (PBS) and proteins were extracted in 50 μL of lysis buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 10% glycerol, and 1% NP-40) supplemented with 10 mM NaF, 1 mM Na3VO4, 10 μg/mL leupeptin, 1 μg/mL pepstatin and aprotinin, and 1 μL/mL phenylmethyl sulfonyl fluoride (PMSF) saturated.',
'output': [{'entity1': 'The cells', 'relationship': 'washed with', 'entity2': 'phosphate-buffered saline'},
           {'entity1': 'proteins', 'relationship': 'extracted in', 'entity2': 'lysis buffer'}]}
</sample>
            
<sample>
{'input': 'Human primary monocytes were prepared from buffy coats of three healthy human blood donors.', 
'output': [{'entity1': 'Human primary monocytes', 'relationship': 'prepared from', 'entity2': 'buffy coats of healthy human blood donors'}]}
</sample>

<sample>
{'input': 'Monocytes were incubated with LPS (10 ng/mL, Salmonella typhimurium SL1181) for 30 min before treatment with either the Veh., or c-MIM-2 for an additional 24 hours.',
'output': [{'entity1': 'Monocytes', 'relationship': 'incubated with', 'entity2': 'LPS'},
           {'entity1': 'Monocytes', 'relationship': 'treatment with', 'entity2': 'Veh.'},
           {'entity1': 'Monocytes', 'relationship': 'treatment with', 'entity2': 'c-MIM-2'}]} 
</sample>

<sample>
{'input': 'Human CD14+ monocytes were isolated from the blood of a healthy donor (67 years old man).',
'output': [{'entity1': 'Human CD14+ monocytes', 'relationship': 'isolated from', 'entity2': 'the blood of a healthy donor'}]}
</sample>

<sample>
{'input': 'Monocytes were then cultivated for 6 days in 24-well plates, with α-MEM medium supplemented with 10% fetal bovine serum (FBS) and 100 ng/mL macrophage colony-stimulating factor (M-CSF) (R&D Systems, Inc., Minneapolis, MN, USA, Ref: #216-MC).', 
'output': [{'entity1': 'Monocytes', 'relationship': 'cultivated in', 'entity2': '24-well plates'},
           {'entity1': 'α-MEM medium', 'relationship': 'supplemented with', 'entity2': 'fetal bovine serum'}, 
           {'entity1': 'α-MEM medium', 'relationship': 'supplemented with', 'entity2': 'macrophage colony-stimulating factor'}]}
</sample>
            
<sample>
{'input': 'Human primary granulocytes were freshly isolated from the blood of a healthy donor obtained from the EFS, and seeded in 48-well plates in optimized RPMI 1640 supplemented with 10% inactivated FBS.',
'output': [{'entity1': 'Human primary granulocytes', 'relationship': 'isolated from', 'entity2': 'the blood of a healthy donor'},
           {'entity1': 'Human primary granulocytes', 'relationship': 'seeded in', 'entity2': '48-well plates'},
           {'entity1': 'optimized RPMI 1640', 'relationship': 'supplemented with', 'entity2': 'inactivated FBS'}]}
</sample>
2024-04-05 02:31:33,331 - INFO - root - Processed Output: [{'input': 'Human peripheral blood mononuclear cells (PBMC) from healthy adult volunteer donors were isolated by centrifugation of venous blood on Ficoll-Hypaque density gradients (Amersham Pharmacia Biotech, Piscataway, NJ, USA).', 'output': [{'entity1': 'Human peripheral blood mononuclear cells', 'relationship': 'isolated from', 'entity2': 'venous blood'}, {'entity1': 'venous blood', 'relationship': 'centrifugation on', 'entity2': 'Ficoll-Hypaque density gradients'}]}, {'input': 'Cells (105/mL) were cultured in 24-well round-bottom plates in 2 mL of complete medium and stimulated with phytohemagglutinin (PHA) (5 μg/mL) for 48 hours.', 'output': [{'entity1': 'Cells', 'relationship': 'cultured in', 'entity2': '24-well round-bottom plates'}, {'entity1': 'Cells', 'relationship': 'stimulated with', 'entity2': 'phytohemagglutinin'}]}, {'input': 'The SN were collected and stored at −80°C until use.', 'output': [{'entity1': 'The SN', 'relationship': 'collected and stored at', 'entity2': '-80°C'}]}, {'input': 'Human Colonic Epithelial Cells (HCoEpiC) were purchased from Innoprot, Bizkaia, Spain.', 'output': [{'entity1': 'Human Colonic Epithelial Cells', 'relationship': 'purchased from', 'entity2': 'Innoprot, Bizkaia, Spain'}]}, {'input': 'The cells were seeded at the density of 5×105 cells in 24-well plate inserts whose diameter is 6.5 mm and the membrane area 0.3 cm2 and grown until tight confluence.', 'output': [{'entity1': 'The cells', 'relationship': 'seeded at', 'entity2': 'density of 5×105 cells'}, {'entity1': 'The cells', 'relationship': 'grown until', 'entity2': 'tight confluence'}]}, {'input': 'The trans-epithelial resistance (TEER) measurements were obtained as Ω/cm2 and performed with a Millicell® ERS-2 device at different incubation times (24 hours and 72 hours), in the presence/absence of the PBMC SN, with/without c-MIM-4 or Veh. added 30 minutes before reading.', 'output': [{'entity1': 'The trans-epithelial resistance measurements', 'relationship': 'obtained as', 'entity2': 'Ω/cm2'}, {'entity1': 'The trans-epithelial resistance measurements', 'relationship': 'performed with', 'entity2': 'Millicell® ERS-2 device'}, {'entity1': 'The trans-epithelial resistance measurements', 'relationship': 'performed at', 'entity2': 'different incubation times'}, {'entity1': 'c-MIM-4', 'relationship': 'added', 'entity2': 'The trans-epithelial resistance measurements'}, {'entity1': 'Veh.', 'relationship': 'added', 'entity2': 'The trans-epithelial resistance measurements'}]}, {'input': '10 mM of sodium caprate (C10) (Sigma-Aldrich, ref # C4151) was used as a positive control.', 'output': [{'entity1': 'sodium caprate', 'relationship': 'used as', 'entity2': 'a positive control'}]}, {'input': 'HCoEpiC cells were treated with or without Veh. or c-MIM-1 for 24 h.', 'output': [{'entity1': 'HCoEpiC cells', 'relationship': 'treated with', 'entity2': 'Veh.'}, {'entity1': 'HCoEpiC cells', 'relationship': 'treated with', 'entity2': 'c-MIM-1'}]}, {'input': 'After that, 400 μL of human PBMC SN previously activated with PHA during 48 h was added to each well for 30 minutes.', 'output': [{'entity1': 'human PBMC SN', 'relationship': 'activated with', 'entity2': 'PHA'}, {'entity1': 'human PBMC SN', 'relationship': 'added to', 'entity2': 'each well'}]}, {'input': 'For quantitative reverse transcriptase-PCR assays, total RNA (1 μg) was retrotranscribed using the iScript cDNA Synthesis Kit (Ref #1708891, Bio-Rad, Hercules, CA, USA) and the cDNA was analyzed by real-time PCR using the iQTM SYBR Green Supermix (Ref #1708880, Bio-Rad) and a CFX96 Real-time PCR Detection System (Bio-Rad).', 'output': [{'entity1': 'total RNA', 'relationship': 'retrotranscribed using', 'entity2': 'iScript cDNA Synthesis Kit'}, {'entity1': 'the cDNA', 'relationship': 'analyzed by', 'entity2': 'real-time PCR'}, {'entity1': 'real-time PCR', 'relationship': 'using', 'entity2': 'iQTM SYBR Green Supermix'}, {'entity1': 'real-time PCR', 'relationship': 'using', 'entity2': 'CFX96 Real-time PCR Detection System'}]}, {'input': 'Claudin-1: F: 5’-AGG TCT GGC GAC ATT AGT GG-3’; R: 5’-CGT GGT GTT GGG TAA GAG GT-3’; GAPDH: F: 3’-TGG CAA AGT GGA GAT TGT TGC C-3’; R: 5’-AAG ATG GTG ATG GGC TTC CCG-3’.', 'output': [{'entity1': 'Claudin-1', 'relationship': 'F', 'entity2': '5’-AGG TCT GGC GAC ATT AGT GG-3’'}, {'entity1': 'Claudin-1', 'relationship': 'R', 'entity2': '5’-CGT GGT GTT GGG TAA GAG GT-3’'}, {'entity1': 'GAPDH', 'relationship': 'F', 'entity2': '3’-TGG CAA AGT GGA GAT TGT TGC C-3’'}, {'entity1': 'GAPDH', 'relationship': 'R', 'entity2': '5’-AAG ATG GTG ATG GGC TTC CCG-3’'}]}, {'input': 'The cells were washed with phosphate-buffered saline (PBS) and proteins were extracted in 50 μL of lysis buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 10% glycerol, and 1% NP-40) supplemented with 10 mM NaF, 1 mM Na3VO4, 10 μg/mL leupeptin, 1 μg/mL pepstatin and aprotinin, and 1 μL/mL phenylmethyl sulfonyl fluoride (PMSF) saturated.', 'output': [{'entity1': 'The cells', 'relationship': 'washed with', 'entity2': 'phosphate-buffered saline'}, {'entity1': 'proteins', 'relationship': 'extracted in', 'entity2': 'lysis buffer'}]}, {'input': 'Human primary monocytes were prepared from buffy coats of three healthy human blood donors.', 'output': [{'entity1': 'Human primary monocytes', 'relationship': 'prepared from', 'entity2': 'buffy coats of healthy human blood donors'}]}, {'input': 'Monocytes were incubated with LPS (10 ng/mL, Salmonella typhimurium SL1181) for 30 min before treatment with either the Veh., or c-MIM-2 for an additional 24 hours.', 'output': [{'entity1': 'Monocytes', 'relationship': 'incubated with', 'entity2': 'LPS'}, {'entity1': 'Monocytes', 'relationship': 'treatment with', 'entity2': 'Veh.'}, {'entity1': 'Monocytes', 'relationship': 'treatment with', 'entity2': 'c-MIM-2'}]}, {'input': 'Human CD14+ monocytes were isolated from the blood of a healthy donor (67 years old man).', 'output': [{'entity1': 'Human CD14+ monocytes', 'relationship': 'isolated from', 'entity2': 'the blood of a healthy donor'}]}, {'input': 'Monocytes were then cultivated for 6 days in 24-well plates, with α-MEM medium supplemented with 10% fetal bovine serum (FBS) and 100 ng/mL macrophage colony-stimulating factor (M-CSF) (R&D Systems, Inc., Minneapolis, MN, USA, Ref: #216-MC).', 'output': [{'entity1': 'Monocytes', 'relationship': 'cultivated in', 'entity2': '24-well plates'}, {'entity1': 'α-MEM medium', 'relationship': 'supplemented with', 'entity2': 'fetal bovine serum'}, {'entity1': 'α-MEM medium', 'relationship': 'supplemented with', 'entity2': 'macrophage colony-stimulating factor'}]}, {'input': 'Human primary granulocytes were freshly isolated from the blood of a healthy donor obtained from the EFS, and seeded in 48-well plates in optimized RPMI 1640 supplemented with 10% inactivated FBS.', 'output': [{'entity1': 'Human primary granulocytes', 'relationship': 'isolated from', 'entity2': 'the blood of a healthy donor'}, {'entity1': 'Human primary granulocytes', 'relationship': 'seeded in', 'entity2': '48-well plates'}, {'entity1': 'optimized RPMI 1640', 'relationship': 'supplemented with', 'entity2': 'inactivated FBS'}]}]
2024-04-05 02:31:33,352 - INFO - root - New Rows:      id                                              input                                             output
0   531  Human peripheral blood mononuclear cells (PBMC...  [{'entity1': 'Human peripheral blood mononucle...
1   532  Cells (105/mL) were cultured in 24-well round-...  [{'entity1': 'Cells', 'relationship': 'culture...
2   533  The SN were collected and stored at −80°C unti...  [{'entity1': 'The SN', 'relationship': 'collec...
3   534  Human Colonic Epithelial Cells (HCoEpiC) were ...  [{'entity1': 'Human Colonic Epithelial Cells',...
4   535  The cells were seeded at the density of 5×105 ...  [{'entity1': 'The cells', 'relationship': 'see...
5   536  The trans-epithelial resistance (TEER) measure...  [{'entity1': 'The trans-epithelial resistance ...
6   537  10 mM of sodium caprate (C10) (Sigma-Aldrich, ...  [{'entity1': 'sodium caprate', 'relationship':...
7   538  HCoEpiC cells were treated with or without Veh...  [{'entity1': 'HCoEpiC cells', 'relationship': ...
8   539  After that, 400 μL of human PBMC SN previously...  [{'entity1': 'human PBMC SN', 'relationship': ...
9   540  For quantitative reverse transcriptase-PCR ass...  [{'entity1': 'total RNA', 'relationship': 'ret...
10  541  Claudin-1: F: 5’-AGG TCT GGC GAC ATT AGT GG-3’...  [{'entity1': 'Claudin-1', 'relationship': 'F',...
11  542  The cells were washed with phosphate-buffered ...  [{'entity1': 'The cells', 'relationship': 'was...
12  543  Human primary monocytes were prepared from buf...  [{'entity1': 'Human primary monocytes', 'relat...
13  544  Monocytes were incubated with LPS (10 ng/mL, S...  [{'entity1': 'Monocytes', 'relationship': 'inc...
14  545  Human CD14+ monocytes were isolated from the b...  [{'entity1': 'Human CD14+ monocytes', 'relatio...
15  546  Monocytes were then cultivated for 6 days in 2...  [{'entity1': 'Monocytes', 'relationship': 'cul...
16  547  Human primary granulocytes were freshly isolat...  [{'entity1': 'Human primary granulocytes', 're...
2024-04-05 02:31:33,360 - INFO - root - Successfully saved to dataframe!
2024-04-05 02:31:33,366 - INFO - root - Processing chunks 5/14
2024-04-05 02:31:57,593 - INFO - httpx - HTTP Request: POST https://api.anthropic.com/v1/complete "HTTP/1.1 200 OK"
2024-04-05 02:31:57,595 - INFO - root - Prediction:  Here are the samples extracted from the given article:

<sample>
{
  "input": "Rat cortical neurons were cultured as described by Singer et al28  Briefly, a pregnant female rat of 15 days gestation was sacrificed by CO2  inhalation and the fetuses were removed from the uterus.",
  "output": [{"entity1": "Rat cortical neurons", "relationship": "cultured", "entity2": null}]
}
</sample>

<sample>
{
  "input": "The cortexes were removed and placed in ice-cold medium of Leibovitz containing 2% of penicillin/streptomycin and bovine serum albumin.", 
  "output": [{"entity1": "cortexes", "relationship": "removed", "entity2": null},
            {"entity1": "cortexes", "relationship": "placed", "entity2": "ice-cold medium"}]  
}
</sample>

<sample>
{
  "input": "Cortexes were dissociated by trypsin-EDTA for 20 min at 37°C.",
  "output": [{"entity1": "Cortexes", "relationship": "dissociated", "entity2": "trypsin-EDTA"}]
}
</sample>

<sample>
{
  "input": "Cells were then centrifuged at 290 × g for 10 min at 4°C.",
  "output": [{"entity1": "Cells", "relationship": "centrifuged", "entity2": null}]  
}
</sample>

<sample>
{
  "input": "Glial cells were seeded at the same time as the neurons at a density of 20.000 cells per well.",
  "output": [{"entity1": "Glial cells", "relationship": "seeded", "entity2": "neurons"},
            {"entity1": "Glial cells", "relationship": "density", "entity2": "20,000 cells per well"}]
}  
</sample>

<sample>
{
  "input": "After 8 days of coculture, cells were treated with either Veh., c-MIM-2, or MK801 at 20 μM in medium for neurons.",
  "output": [{"entity1": "cells", "relationship": "treated", "entity2": "Veh."}, 
            {"entity1": "cells", "relationship": "treated", "entity2": "c-MIM-2"},
            {"entity1": "cells", "relationship": "treated", "entity2": "MK801"}]
}
</sample>

<sample>
{
  "input": "Cells were incubated in a medium for neurons with and without the tested items for an additional 48 hours to analyze the survival of neurons.",
  "output": [{"entity1": "Cells", "relationship": "incubated", "entity2": "medium"},
            {"entity1": "tested items", "relationship": "analyze", "entity2": "survival of neurons"}]
}
</sample>

I have extracted 7 samples with relevant medical entities and relationships from the given article section. Please let me know if you need any clarification or have additional requirements for the samples.
2024-04-05 02:31:57,596 - ERROR - root - Error generating predictions: name 'null' is not defined
2024-04-05 02:31:57,596 - ERROR - root - Error generating training data!
